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Introduction
Cigarette smoking is associated with lung cancer, cardiovascular disease, and chronic
respiratory conditions. It is responsible for high mortality and morbidity risk in the US
population. Smokers find sudden quitting difficult and it is reported that a large number of
unassisted quitting attempts are eventually unsuccessful. Electronic cigarette or e-cig is a
novel battery-driven, nicotine delivery product, currently being used as a smoking
cessation tool by current and former smokers. Since its resemblance to a conventional
cigarette, and its non-combustible nature, e-cig use has risen exponentially in the last few
years. To address such public health issues, the US FDA is working on formulating

regulations to manufacture, market, and distribute e-cigs has called for research evidence
on the long term use of e-cig use.
Objective
The objective of this study was to develop and validate a Discrete Event Simulation model
to simulate the electronic cigarette (e-cig) use behavior, and to estimate the long term e-cig
use prevalence, in different groups of the US population.
Methods
The model population was generated from analyzing the National Health Interview Survey
data from 2011-2013. The population was categorized into current, recent former, late
former and never smokers. Population birth rates and death rates were applied using the
2012 US Census Bureau data. Model parametrization, transition probabilities and e-cig
related risks were obtained and applied using cross sectional survey and longitudinal e-cig
studies done on US population. The model was run for the period of 15 years and e-cig use
prevalence at the end of the simulation period was estimated. Each simulation was
replicated 100 times using Monte Carlo simulation approach. Model validation was
performed by the use of null and extreme input values (internal validation), examining
programing codes (debugging), verification by tobacco science and system analysis experts
(structural and technical validation), comparison of model’s first year results with CDC
reports (external validation).

Conclusion
Total projected e-cig prevalence in the US population at the end of simulation of period was
found to be around 19%. The results showed a gradual reduction in the number of
conventional cigarette smokers and an increase in the e-cig users over the simulation
period. Highest e-cig users were <21 years old, male, white and had less than high school
level education. Sensitivity analyses of various model parameters showed that the e-cig
prevalence was most sensitive to the impact and timing of policy implementation.
As a novel nicotine delivery system, e-cigs are rapidly gaining acceptance in the US and
recent reports have shown an exponential rise in the popularity of e-cig among minors and
young adults. Our research provides empirical evidence that can be used by the scientific
community and regulatory bodies to formulate regulations for marketing and sales of ecigs in various sections of the population, where the prevalence is expected to rise in
future. Our study can also guide the policy makers to introduce relevant policies at specific
time points when the e-cig use is expected to rise.

Chapter 1
Introduction

1

Background

Cigarette smoking is an important and preventable cause of morbidity in the US associated
with lung cancer, cardiovascular disease, and chronic respiratory conditions. Recent US
health care reports (How tobacco smoke causes disease.2010; Health consequence of
smoking: US surgeon general report.2014) have shown that smokers are at greater risk than
non-smokers for diseases that affect the heart and blood vessels (cardiovascular disease),
eventually leading to stroke and coronary heart disease. Further, smoking can cause lung
diseases by damaging the airways and the small air sacs (alveoli) found in the lungs. This
leads to COPD, which includes emphysema and chronic bronchitis (Health consequence of
smoking: US surgeon general report.2014). Cigarette smoking also causes most cases of lung
cancer in the country (How tobacco smoke causes disease.2010; Health consequence of
smoking: US surgeon general report.2014). In terms of mortality, the US Centers for Disease
Control and Prevention (CDC) reports that approximately 443,000 deaths occur annually in
the US due to smoking, including those from secondhand smoke (Agaku, King, Husten, &
Bunnell, 2014).
Along with negative health effects, smoking also results in a high economic burden. Annual
smoking-attributable economic costs in the United States estimated for the years 2009–
2012 were more than $289 billion, which included approximately $133 billion for direct
medical care of adults and more than $156 billion for indirect costs due to lost productivity
(Health consequence of smoking: US surgeon general report.2014).

Although cigarette smoking is declining among U.S. adults over the past five decades, there
is still a high proportion of population smoking cigarettes and other tobacco products
(Agaku et al., 2014). During 2012–2013, the US surgeon general report identified
approximately one in five U.S. adults (total of 50 million persons) used any tobacco product
every day or some days, and an estimated 60 million people used tobacco products every
day, some days, or rarely (How tobacco smoke causes disease.2010; Health consequence of
smoking: US surgeon general report.2014) . The majority of the smoking population
consisted of young adults and teenagers. A report from the Center of disease control and
prevention (CDC) indicated that the prevalence of current tobacco product use among
middle and high school students was 6.7% and 23.3%, respectively (CDC morbidity and
mortality report.2013).
Offering help to quitting tobacco use in people addicted to nicotine is one of the most
important policies identified by the World Health Organization (WHO) Framework
Convention on Tobacco Control (FCTC) to expand the fight against the tobacco epidemic
(WHO.2012). However, due to the addictive nature of nicotine, most of the smokers are biobehaviorally addicted. That is, not only they are dependent on the biological constituents of
tobacco, but are also dependent on the behavior aspect of using tobacco products like
holding and puffing on cigarettes.
Quitting smoking can be very difficult and is often accompanied by variety of withdrawal
symptoms (Benowitz, 1991). Approximately, 70% of smokers try to quit, but less than 5%
of unassisted attempts are successful (Benowitz, 1991). Sudden quitting may also result in
fatigue, dizziness, nicotine withdrawal, irritability, anger, frustration, sad mood, anxiety,

decreased concentration, hunger, insomnia, restlessness, decreased heart rate, weight gain
and an eventual relapse of smoking (Benowitz, 1991; Siegel, Tanwar, & Wood, 2011). Many
smokers intending to quit take help of pharmacotherapy as well as patient counselling but
smokers using these approaches have shown a high rate of an eventual relapse (Bell &
Keane, 2012).
The latest addition to the existing tools for smoking cessation and abstinence is electronic
cigarettes (e-cigs). Launched in China in 2003, e-cigs are hand-held battery-powered
nicotine delivery devices which enable users to inhale doses of vaporized nicotine
(Barbeau, Burda, & Siegel, 2013). A basic model of an e-cig consist of a mouthpiece
comprising of a liquid-filled cartridge mainly filled with variable concentration of nicotine,
concentrated flavors, and a humectant substance such as propylene glycol, vegetable
glycerin or polyethylene glycol (Besaratinia & Tommasi, 2014). An atomizer equipped with
an electronic controller, sensor, and battery powered heater converts the liquid inside the
cartridge into vapor that mimics the cigarette smoke, with a colored LED simulating a
burning cigarette tip. Used e-cig cartridges can be replaced or refilled with a new cartridge,
which is readily available in any e-cig store (Besaratinia & Tommasi, 2014). Since no
tobacco is burned, inhaling nicotine via e-cigs provides a potentially safer alternative to
smoking regular cigarette since it eliminates the harmful tars and carbon monoxide
(Dawkins, Turner, Hasna, & Soar, 2012). E-cigs therefore are often perceived to help in
cigarette smoking cessation and reduction (Dawkins et al., 2012). It also reduces the
problems of second hand and third hand smoke. (Barbeau et al., 2013; Siegel et al., 2011;
Zhu et al., 2013).

Rise in the use of e-cigs and related effects
As a novel nicotine delivery system, e-cig are rapidly gaining acceptance in the US and
many parts of the world. Currently, the global e-cig market is worth $6 billion and in the US
alone, the estimated e-cig retail sales approached $2 billion at the end of 2013, and is
estimated to rise to $10 billion by 2017 (Herzog, 2013). It is anticipated that e-cig sales will
surpass that of conventional tobacco cigarettes by 2023 (Herzog, 2013). According to a
study by the Centers for Disease Control and Prevention (CDC), nearly 6% of all U.S. adults
have used e-cig, and approximately 21% of American adult smokers (i.e., an estimated
population of 45 millions) have tried e-cig in the past (CDC morbidity and mortality
report.2013). The Tobacco Vapor Electronic Cigarette Association claims that around 4
million Americans are e-cig users (TVECA, 2013). This increasing trend for e-cig use also
extends to minors as the number of U.S. middle and high school students who tried e-cig
more than doubled between 2011 and 2012, rising from 4.7% to 10% (CDC morbidity and
mortality report.2013). In 2012, around 1.78 million middle and high school students
nationwide admitted to using e-cig. Along with that, 76.3% of youth who used e-cig within
the past 30 days also smoked regular tobacco cigarettes in the same period, giving rise to
dual use (CDC morbidity and mortality report.2013).
Although e-cigs has been portrayed as a less harmful substitute for smokers who are
unable to quit, the counter-argument to the use of e-cig is that it may cause nicotine
dependence in smokers and long term use may cause health complications (Dutra & Glantz,
2014; Tomar, 2007). Despite the fact that the e-cigs deliver fewer amounts of nicotine
vapors than tobacco cigarettes, they nevertheless have showed long term nicotine

dependency in e-cig users (Tomar, 2007). Also, recent studies done on chemical analysis of
e-cig vapor/liquid has shown the presence of toxins and carcinogens, generally at lower
levels, in various e-cig products (Goniewicz, Kuma, Gawron, Knysak, & Kosmider, 2013;
Kim & Shin, 2013; McAuley, Hopke, Zhao, & Babaian, 2012).

The rising popularity of e-cig among minors and young adults is particularly concerning
because these products may serve as a ‘gateway’ to using conventional tobacco products. In
other words, e-cigs use has potential unintended consequences, such as becoming “starter
products” for non-smokers, especially young adults, leading to increased smoking initiation
and derailing the potential for ultimate smoking abstinence (Pepper et al., 2013; Riker, Lee,
Darville, & Hahn, 2012). Because the vast majority of smokers pick up the habit as
teenagers (Pearson, Richardson, Niaura, Vallone, & Abrams, 2012), the excessive use of ecig by teenagers and young adults is a critical concern because it may ultimately lead to
long lasting smoking habits.
The use of e-cig also draws attention to the increasing trend of dual use claiming that
smokers may use e-cig to temporarily alleviate their craving for tobacco cigarettes,
especially in settings where smoking is prohibited. Under such assumption, dual users may
take advantage of e-cig as a ‘quick fix’, and maintain their smoking status without feeling
the need to quit smoking (Pepper et al., 2013).

Regulatory Perspective to the use of e-cig
The WHO stated that the efficacy of e-cig in aiding smoking cessation had not been
demonstrated scientifically, and recommended that consumers should be advised not to
use e-cig until the recognized regulatory bodies have found them safe and effective
(WHO.2012). Since then, several countries such as Australia and Canada have restricted the
sale of e-cigs until pending review by their regulatory agencies (WHO.2012). At present, the
FDA is formulating regulations for the sale and marketing of e-cig as a smoking cessation
product. However, the nature of the regulation procedure is yet to be determined as there
is a lack of research evidence on the health impact of using e-cigs (WHO.2012; Henningfield
& Zaatari, 2010).
In the US, with the enactment of the Family Smoking Prevention and Tobacco Control Act
(FSPTCA) in 2009, the FDA was granted authority to regulate the manufacture, marketing,
and distribution of tobacco products to protect the public health and to reduce tobacco use
by minors (Family smoking prevention and tobacco control act (FSPTCA).2014). Within the
framework of the FSPTCA, the FDA and the National Institutes of Health (NIH) have formed
an interagency partnership to foster research relevant to tobacco regulatory science, and
identified multiple research opportunities, including e-cig initiation, use (including
transition to other tobacco products and multiple use), perceptions, dependence, and
toxicity (Tobacco regulatory science program (TRSP).2014).

The ongoing and future research on these topics is expected to provide empirical evidence
that can be used to inform the general public, scientific community, and regulatory

authorities of the health risks and benefits associated with e-cig use. Not only will this
information help generate further interests for scientists in the field of tobacco regulatory
research, but it will also assist the regulatory agencies in making scientifically based
decisions on the development and evaluation of regulations on novel tobacco products
such as e-cigs to ensure safety of public health.

Chapter 2

Literature Review

Tobacco use is a global phenomenon, affecting an estimated 1.2 billion people, which poses
substantial health burden and costs. With approximately 5 million tobacco-related deaths
annually, cigarette smoking is the leading cause of preventable premature mortality in the
world (World health organization.1997). The risk of serious disease diminishes rapidly
after quitting and permanent abstinence is known to reduce the risk of lung cancer, heart
disease, chronic lung disease, stroke, and stroke (Health consequence of smoking: US
surgeon general report.2014; Lightwood & Glantz, 1997).
Existing treatments for smoking cessation includes various methods, from simple medical
advice to pharmacotherapy. However, the potential addictive nature of nicotine creates a
huge obstacle for those who desire to quit smoking. It has been shown that approximately
80% of smokers who attempt to quit on their own relapse within the first month of
abstinence and only about 3-5% remain abstinent at 6 months (Hughes, Keely, & Naud,
2004).

Smokers often take help of drug therapies to help them quit their smoking habit. The latest
treating tobacco use and dependency guidelines of US Department of Health and Human
Services (How tobacco smoke causes disease.2010)categorizes pharmacotherapy for
treatment of tobacco dependence into first-line (nicotine replacement therapy [NRT],
bupropion, and varenicline) and second-line medications (include nortriptyline and
clonidine). Most of the first line medications have established efficacy profiles but the FDA
has not approved the second line medications for tobacco dependence treatment indication
and there are concerns about their potential side effects (Hays, Ebbert, & Sood, 2009a).

NRT is the most common existing medication used to assist tobacco cessation. It acts by
partially replacing the nicotine formerly obtained from tobacco smoking and aids smoking
cessation by weakening the reinforcing effects of nicotine delivered via tobacco, and
therefore reducing the severity of withdrawal symptoms and cravings (Gross & Stitzer,
1989). Despite the first line treatment, NRT does not completely eliminate all symptoms of
withdrawal because the delivery system does not reproduce the rapid and high levels of
nicotine achieved through regular tobacco use. (Benowitz, 1991). Differences in
formulations (lozenge, gum, patch, nasal spray, and inhaler) may provide some relief to the
withdrawal symptoms or urges to smoke, but there is little direct evidence that one
nicotine product is more effective than another (Benowitz, 1991). In general, NRT is
considered to be safe for most patients, with a relatively low rate of discontinuation due to
adverse events (Tonnesen & Mikkelsen, 2000).

Bupropion hydrochloride (brand names: Zyban, Wellbutrin), another first line smoking
cessation drug is found to be effective as a smoking-cessation aid, with sustained-release
(SR) oral formulations as well as immediate release. The mode of action of bupropion in
smoking cessation is not clearly explained but inhibition of neuronal reuptake of dopamine
and a weak nAChR antagonist effect are thought to contribute to the reported reduction in
the severity of nicotine cravings and withdrawal symptoms (Jorenby, 2002). Pooled
analyses of studies with bupropion generally show quit-rates similar to those observed
with NRT (Hughes, Stead, Hartmann-Boyce, Cahill, & Lancaster, 2014). However, bupropion
have been commonly associated with insomnia and dry mouth (Hughes et al., 2014).

Varenicline (brand names: Chantix/Champix1), launched in 2006, became the first new
prescription drug for smoking cessation in 10 years. Varenicline acts by dual effects: partial
stimulation of nAChRs, without creating the full effect of nicotine (agonist action), and
blocking nAChRs, which prevents the nicotine from tobacco from reaching them
(antagonist action) (Tonstad et al., 2006). These effects provide relief from the cravings
and withdrawal symptoms experienced during smoking cessation (Tonstad et al., 2006).
Varenicline is generally well tolerated, however it is still associated with adverse effects
including nausea, insomnia, gastrointestinal upsets and headache (Hughes et al., 2014). The
prescribing information for varenicline also carries a black-box warning highlighting an
increased risk of psychiatric symptoms and suicidal ideation in patients reporting any
history of psychiatric illness (Tonstad et al., 2006).

Both nortryptiline and clonidine are second-line medications for treatment of tobacco
dependence but they do not have approval from the US FDA for this indication, as there are
concerns about potential side effects (Fiore, 2000). Combinations of smoking-cessation
medications such as nicotine patch plus a more rapid release NRT such as gum, lozenge or
spray, or bupropion plus NRT, have shown to increase efficacy in smoking cessation
compared to monotherapy (Fiore, 2000).

The use of e-cigs, also referred to as vaping, is a relatively new phenomenon that is rapidly
gaining the interest of many long-time tobacco users and health care professionals. E-cigs
are becoming a preferred alternative for nicotine delivery among many smokers because of
their realistic look, feel, and taste compared to traditional cigarettes. Furthermore, many

cigarette smokers have turned to vaping because e-cigs vendors are marketing their
product as a cheaper and safer smokeless alternative to traditional cigarettes, and a
possible smoking cessation tool (Herzog, 2013). Awareness and vaping of e-cigs has
increased exponentially in recent years. Data obtained from surveys and smoking reports
showed that in the US, awareness of e-cigs rose from 40.9–57.9% from 2010 to 2011, with
e-cigs use rising from 3.3–6.2% over the same time period [King et al. 2013].

Conceptual framework

The substitution of conventional tobacco products by newer e-cigs draws similarity from
effective patient behavior changes, which are required to help maintain and improve

health, reduce disease risks, and control illnesses. Most of the successful health programs
and interventions are based on an understanding of patient’s health behaviors with respect
to different contexts. Several different approaches or interventions are currently observed
to be practiced by health care providers to modify patient behavior. The most commonly
targeted behaviors are tobacco use, diet and physical activity patterns, alcohol
consumption, medication adherence, unsafe sexual behavior, and preventive behavior such
as screening and vaccinations (Ashenden, Silagy, & Weller, 1997; Grol & Grimshaw, 2003).

Literature shows it is highly difficult for patients to completely quit a long-term habit at
once, such as smoking or alcoholism (Hays, Ebbert, & Sood, 2009b). It is observed that
counseling patients to completely stop smoking or consuming alcohol does not deter
patients’ habits and results in withdrawal symptoms and other stressful conditions.
Clinicians and therapists are observed to offer alternative pharmacotherapies (nicotine
replacement therapy), substitute but less harmful products or group and individual
counseling to patients wanting to quit. It is a proven fact that offering these alternatives
and less harmful products (substitute products) ends up being more successful in reaching
eventual abstinence than asking them to completely quit their habit (Ashenden et al.,
1997). Along with offering substitute products, exposing patients to threats and benefits of
a particular behavior also helps to achieve a health related action (Grol & Grimshaw, 2003).
In context of the behavior of tobacco use or cigarette smoking, it is an addiction that is
difficult to break. Smokers trying to quit have to cope simultaneously with the
psychological and pharmacologic aspects of tobacco dependence (Polosa & Benowitz,

2011). Along with the pharmacological effects of nicotine which results in symptoms like
nausea, insomnia, fatigue, restlessness and increased cardiovascular rhythm, it is crucial to
note the importance of behavioral aspects of tobacco dependence. The rising popularity of
e-cigs can be attributed to their ability to deal with both the pharmacological (i.e. nicotine)
and the behavioral component (similar shape, mechanism and pleasure) of smoking
addiction. Most of the drug therapies do not deal with the behavioral aspects of smoking
cigarettes. E-cigs, on the other hand, provide simulation of smoking behavior with its
physical similarity with a conventional cigarette and the feeling of inhaling and exhaling
smoke, which are important determinants of its effectiveness in reducing or substituting
cigarette smoking.
Along with pacifying the withdrawal symptoms of nicotine, the action of using an e-cig is
also perceived to protect the smokers from getting smoking-related diseases and overcome
other negative effects such as social unacceptability among family and friends. The
potential benefit of an e-cig in addition to lower barriers associated with the use of e-cigs
which include experiencing the same pleasure as tobacco cigarette, habitual of inhaling
smoke, price-difference between e-cig and regular cigarette, and handling and carrying
issues results in high acceptability of e-cigs among the youth and adult smoking population.
The high awareness of e-cig via media advertising, observing other people using it and easy
accessibility and availability of e-cig also contributes to its successful initiation among
different sections of the population.

Impact on public health

Despite the fact that the e-cigs deliver fewer amounts of nicotine vapors than tobacco
cigarettes, they nevertheless have showed long term dependency in e-cig users (Tomar,
2007). To counter this, the proponents of e-cigs claim that use of e-cigs is safer because
tobacco is not combusted and there is no inhalation of the toxins found in cigarette smoke
(Barbeau et al., 2013). However, the FDA has reported that e-cig cartridges and solutions
contain nitrosamines, di-ethylene glycol, and other contaminants potentially harmful to
humans (Westenberger, 2009). Based on this, the FDA wants the sale of e-cigs to be
prohibited or regulated as dangerous nicotine delivery systems that should comply with
the safety standards of the Federal Food Drug and Cosmetic Act (FDCA.2013).
Studies conducted by Foulds et al. (Foulds, Veldheer, & Berg, 2011) believe that more
research needs to be conducted to determine the safety and efficacy of e-cigs as a smoking
cessation tool. However, they also stated that individuals who have successfully quit
smoking in favor of vaping should continue to use e-cigs as a healthier alternative to
conventional cigarettes. E-cigs could play an important role in the future of smoking
cessation, but their use is currently under scrutiny by a complicated legal and political
issues. It is evident that there is a need to conduct more research on the long-term effect
and net benefits of e-cigs, to be able to formulate the control measures which will
streamline the legal and political ramifications surrounding these products.
The potential health hazards of nicotine addiction from other smokeless tobacco products
have been previously published by the American Heart Association and include
hemodynamic effects, endothelial dysfunction, thrombogenesis, systemic inflammation,
and other metabolic effects (Piano et al., 2010). Because of that, there is a concern that

increased availability of e-cigs could increase worldwide nicotine dependence, especially
among the young as they are enticed by the various flavor options e-cigs have to offer. Also,
since vaping does not produce smoke from burning tobacco, the opponents of e-cigs fear
that traditional smokers will substitute vaping for smoking in settings where smoking is
not permitted without any real intention of quitting conventional cigarettes. Furthermore,
vaping in public places could possibly undermine or weaken current antismoking
regulations.
In order to face these challenges, it is very important to become more familiar with the
available scientific evidence- based literature concerning e-cig and vaping. Currently, the
literature is limited, but it is growing fast and more studies are getting published in the
areas of e-cig based surveys studies, chemical analysis of e-cigarette cartridges, nicotine
content, delivery, and clinical and physiological studies, and evaluating long term effect of
vaping. We attempt to comprehensively review the literature published till date on
aforementioned areas and try to address the gap in the current literature. The studies
discussed are categorized on the basis of their study designs including survey design,
experimental, cohort and physiological studies.
Survey studies

The biggest survey study done on e-cig users was done by Adkison et al, to examine the ecig related awareness, use, and product-associated beliefs among current and former
cigarette smokers in the U.S., Canada, Australia, and the UK (Adkison et al., 2013). The
survey was conducted via telephonic interviews from July 2010 to June 2011and the data
were analyzed to explore changes in smoking behavior between e-cig users and non-users.

Results indicated that e-cig awareness ranged from 73% in the U.S. to 20% in Australia.
Among those aware, 16% had tried e-cigs (7.6% of the total sample), and among those who
had tried e-cigs, 39% (2.9% of the sample) were current users. Across countries, awareness
of these relatively new products was higher among younger, non-minority populations
with higher incomes. Trial and use of e-cigs was associated with smoking status and
frequency of smoking, with nondaily smokers being the most likely to try e-cigs, although
there were few non-daily smokers in the sample. Current use was associated with a greater
reduction in cigarettes per day over time, compared to non-e-cig users (among cohort
participants, where data were available); however, users were not more likely to quit
smoking than non-users.

Another four country survey conducted by Etter et al in France, Belgium, Switzerland and
Canada reported the usage patterns of e-cigs, reasons for use, and users' opinions of these
products (Etter, 2010). The results of the study suggested that e-cigs were are mainly
marketed to current smokers either for enjoyment or for use in smoke-free places, and
most people who bought these products were current and former smokers, who used ecigs to help quit smoking, just as they would use NRT. The survey also showed that e-cigs
were used quite intensively by almost all respondents daily and the number puffs per day
was substantial. The studied showed that the users reported more positive than negative
effects with e-cigs and many reported perceived positive effects on the respiratory system
(breathing better, coughing less), compared to regular cigarette smoking. The study also
reported that many respondents reported that the e-cigs helped them quit smoking, and
several compared it favorably with either nicotine patch or bupropion. The respondents

also reported that e-cigs relieved craving and withdrawal, which was an added benefit over
nicotine patches. It was also reported that dry mouth and throat was a frequent adverse
effect of the e-cigs.

A longitudinal survey study done by Etter and Bullen reported the change over time in the
behavior of e-cig users (Etter & Bullen, 2014). Data were collected at the baseline and after
12 months. The study reported information on the natural behavior of an international
cohort of vapers over 12 months outside clinical settings or efficacy trials. The results
reported that most of the e-cig users were former smokers, who used e-cigs much like
nicotine medications, to assist quitting, but with a longer duration of use. Among e-cig
users, a low proportion of former smokers and recent quitters relapsed to smoking. Dual
users of e-cigs and conventional cigarettes were shown to reduce their cigarette
consumption after they started to vape, and about half had stopped smoking at 1-year
follow-up.

Another survey study conducted by Pearson et al, addressed the knowledge gap by using
cross-sectional data from 2 separate surveys conducted in 2010, exclusively on the US
population of e-cig users to estimate e-cig awareness, use, and harm perceptions in the
adult US population (Pearson et al., 2012). The first survey was a nationally representative
survey (Knowledge Networks’ Knowledge Panel) and the second one was from the followup of a large cohort of current smokers and recent former smokers (Legacy Longitudinal
Smoker Cohort (LLSC). The study reported that national estimates of e-cigs ever-use
prevalence was 11.4% for smokers, 2.0% for former smokers, and 0.8% for never smokers.

It also reported that roughly 5 million smokers and more than 1 million former and never
smokers reported to have used e-cigs. Ever use was mostly concentrated among current
smokers, young adults, and non-Hispanic Whites. It was also indicated that the use was
popular among those with a college degree. Current e-cig use was most common among
current smokers (4.1%) and former smokers (0.5%).

A face-to-face survey was conducted by Foulds et al on experienced e-cig users attending a
meeting for e-cig aficionados (e-cig experts), described the e-cig products they used and
discussed the public health issues raised by these products and implications for clinicians
(Foulds et al., 2011). The results of this study were mostly consistent with previous online
or e-mail based surveys of e-cig users and found out that a high proportion had completely
replaced cigarette smoking with e-cig use. Among 3000 ever users of e-cigs, 77% used ecigs to quit smoking or avoid relapsing and 20% stated that they used e-cigs to reduce
tobacco consumption with no intention of quitting smoking. Most of the ex-smokers in that
study (79%) feared that they might relapse to smoking if they stopped using the e-cig.

A more recent 1 year longitudinal e-cig analysis was conducted by Grana et al on a national
sample of current US smokers to determine whether e-cig use predicted successful quitting
or reduced cigarette consumption (Grana, Popova, & Ling, 2014). The participants were
current smokers recruited from the Knowledge Networks probability-based web enabled
panel who completed baseline (November 2011) and follow-up (November 2012) surveys.
The study reported that significantly more women, younger adults, and individuals with
less education used e-cigs. At baseline, a greater proportion of e-cig users reported

smoking their first cigarette less than 30 minutes after waking compared with non-users.
Also, baseline e-cig use was not shown to be significantly associated with greater intention
to quit smoking. E-cig use at baseline did not significantly predict quitting 1 year later. A
second model including intent, consumption, and dependence covariates found that
intention to quit and cigarettes smoked per day significantly predicted quit status while
past 30-day e-cigarette use did not. Among participants who reported smoking at both
baseline and follow-up, e-cigarette use at baseline was not associated with a change in
cigarette consumption, controlling for baseline cigarette consumption.

Siegel et al reported the results of a survey conducted using a non-convenience sampling
frame of all fırst-time purchasers of a particular brand of e-cigs (Siegel et al., 2011). The
survey was done to determine the effectiveness of e-cigs for smoking cessation. The results
of this study showed a 6-month point prevalence of smoking abstinence among the current
e-cig users as 31.0%. Respondents who were not smoking at the 6-month point, or past ecig users, around one-third of them were reported as nicotine-free. Around 67% of
respondents reported a reduction in the number of cigarettes they smoked and around
49% of respondents reported abstinence from smoking.

Dutra et al used the National Youth Tobacco Survey, which recently started to capture the
information related to e-cig use among the youth population, to further examine the
relationship between e-cig use and conventional cigarette smoking and smoking cessation
among US adolescents (Dutra & Glantz, 2014). The data analysis showed that dual use of ecigarettes and conventional cigarettes was high among adolescents and increasing rapidly.

Adolescents who had ever used a cigarette (not even one puff) and used e-cigs, were more
likely to report having smoked at least 100 cigarettes and to be current smokers than
adolescents who never used e-cig. Thus, it showed that the e-cig users were becoming
heavier smokers and less likely to stop smoking cigarettes. These results cast a serious
doubt that e-cigs are effective as smoking cessation aids.

Similar to Dutra and his colleagues, Lee et al used a nationalized database in Korea to
assess the prevalence of e-cig use as well as the relationship between e-cigarette use and
current cigarette smoking, cigarettes per day, attempts to quit conventional cigarettes, and
stopping smoking cigarettes (Lee, Grana, & Glantz, 2014). The findings of this study
reported a high dual use of cigarettes and e-cigs, and that e-cigs were not being used as a
substitute for cigarettes among Korean adolescents. Around 9.4% of Korean adolescents
were found to have ever tried e-cigs and 4.7% were current users. Furthermore, a
significant association between current e-cig use and higher levels of cigarette
consumption was found, compared to ever and never e-cig user. Tenth graders had the
highest e-cig use and 12th graders had the highest conventional cigarette use. The study
also reported that among ever e-cig users, around 85% were dual users. Also, among
current e-cig users, more than 75% were dual users.

Studying the willingness to use and the gateway effect of e-cigs, Pepper et al conducted a
study to understand how male adolescents would respond to e-cigs (Pepper et al., 2013).
The study surveyed a national sample of males ages 11-19 to explore their awareness of e
cigarettes and their willingness to try them, along with the proportion of population

showing dual use. The sample population consisted of parents with sons’ ages 11-17 years
and male adolescents of ages 18-19 years. The results showed that around two thirds were
aware of e-cigs, out of which older adolescents were more likely to be aware of e cigarettes
than younger adolescents, while Hispanic adolescents were less likely to be aware
compared to their non-Hispanic counterparts. The results also showed that nearly 1 in 5
adolescent males were willing to try either a plain or flavored e cigarette. After controlling
for significant correlates, the odds of a smoker being willing to try an e cigarette were 10
times the odds of a nonsmoker.

A large cross-sectional survey of a representative sample of the English population
conducted by Brown et al used data from an ongoing national surveillance program (the
Smoking Toolkit Study) which has been tracking the use of e-cigs as a reported aid to
cessation among the general population in England since July 2009 (Brown, Beard, Kotz,
Michie, & West, 2014). The study aimed to address the question of how effective e-cig were
compared with NRT bought over-the-counter and unaided quitting in the general
population of smokers who were attempting to stop. The primary outcome was selfreported abstinence up to the time of the survey, adjusted for potential confounders
including nicotine dependence. The results showed that the in the study population (5863
smokers), 7.9% had used e-cigarettes, 32.8% had used NRT bought over-the-counter and
59.3% had used no aid to cessation. Quitting method did not differ by sex or the number of
quit attempts in the past year but was associated with age, social grade, time since the quit
attempt started, CPD, smoking less than one CPD, the measures of dependence (time with
and strength of urges and HSI) and whether the attempt had begun abruptly. Further

comparisons showed that those who used either e-cigs or no aid were younger than those
using NRT over-the-counter, and that those who used NRT over-the-counter or no aid were
more likely to hold a lower social grade than those using e-cigarettes. E-cig users smoked
more cigarettes, and were more dependent by the strength of urges measure and heaviness
of smoking index (HIS), than those using no aid.

A more recent study done on e-cig population in Spain by Martinez et al aimed to estimate
the prevalence and analyze the correlates of current and ever use of e-cigarettes, including
purchase location and satisfaction with its use, in a sample of the general population of the
city of Barcelona in 2013 and 2014 (Martinez-Sanchez et al., 2014). The study utilized data
from a survey of representative sample of the adult (n=1245) and asked questions on
current use, ever use and experimentation with e-cigs. The results showed that the
prevalence of ever e-cigarette use was 6.5%, with the population distribution as mean age
of 45.1 years, 56.2% men and 58.3% with intermediate educational level. In total, 75% of ecig users were current cigarette smokers (dual use), 22.9% were former smokers and 2.1%
were never-smokers at the time of the interview. The prevalence of ever e-cig use was
higher among men (8%), younger people (≤44 years old, 13.1%) and people with
intermediate educational level (9.8%). There was a statistically significant association
between ever e-cigarette use and current smoking (OR=54.57) and the highest prevalence
(46.4%) of ever e-cig use was among current smokers with a high cigarette dependence
score.

King et al from the National Center for Chronic Disease Prevention and Health Promotion at
the CDC analyzed data from the 2010 and 2011 “Health Styles” surveys, a consumer panel
survey, to determine estimates of the national prevalence and socio-demographic
correlates of awareness and ever-use of e-cigs among U.S. adults (King, Alam, Promoff,
Arrazola, & Dube, 2013). The survey results showed that the awareness and use of e-cigs
were increasing rapidly. Approximately 6 in 10 adults were found to be aware of e-cigs in
2011 compared with 4 in 10 adults in 2010. Moreover, in 2011, 6.2% of all adults and
21.2% of current smokers had ever used e-cigs, representing an approximate doubling of
2010 estimates. Differences in awareness and use of e-cigs were observed across
subpopulations such as adults <65 years of age, non-Hispanic Whites, and current and
former smokers were most aware of e-cigs. Current smokers were significantly higher
users of e-cigs than non-smokers.

Experimental studies

Since the launch of the e-cig, there have been couple of randomized controlled trials
performed on the e-cig users. The randomized controlled trial conducted by Bullen et al
from 2011 till 2013 in New Zealand, aimed to assess whether nicotine e-cigs were more
effective for smoking cessation than nicotine patches, and included a blind comparison
with e-cigs containing no nicotine (placebo e-cig) (Bullen et al., 2013). The results showed a
significant reduction of the mean cigarette consumption by two cigarettes per day more in
the nicotine e-cigs group than the patches group (P = 0.002). It was also observed that 57%
of the e-cigs group reduced daily cigarettes by at least half at 6 months than in the nicotine
patches group(41%; P = 0.0002) and in the placebo e-cig group (45%; P = 0.08). The results

also showed an abstinence at 6 months after quit day of 7.3% in the nicotine e-cig group, of
5.8% in the nicotine patches group (5.8%), and of 4.1% in the placebo e-cig group.
Moreover, time to relapse in the nicotine e-cig group was observed to be 35 days, more
than twice as long as in the patches group (14 days) or placebo e-cigarettes group (12
days).

The ECLAT trial (Efficiency and safety of an electronic cigarette) was a prospective 12month, double-blind, randomized controlled trial conducted by Caponnetto and his
colleagues in Italy, during the period June 2010– February 2011 (Caponnetto et al., 2013).
It was designed to assess the efficacy and safety of e-cigs loaded with different strengths of
nicotine (7.2 mg, 5.4 mg and no nicotine cartridges). The results of this study showed a
decline in cigarette per day used in all three groups, with no consistent differences among
study groups. Smoking reduction was reported documented in 22.3% and 10.3% at Weeks
12 and 52, respectively. Complete abstinence from tobacco smoking was reported as 11%,
17% and 4% in the three arms respectively, at week 12 and 13%, 9% and 4% in the three
arms respectively at week 52 (P= 0.001 versus baseline).

In another smaller scale trial in terms of participants, Dawkins et al chose 86 e-cig naive
smokers and randomly allocated them to either 18 mg nicotine e-cig (nicotine), 0 mg e-cig
(placebo) or just hold the e-cig (just hold) groups (Dawkins et al., 2012). The study
reported that desire to smoke declined over time for both nicotine and placebo groups
relative to the just hold group. After using the e-cig, the mean desire to smoke score

significantly changed from 4.5 (at baseline) to 2.5, 20 min after use (P=0.05). The difference
was found to be statistically significant for males and females from baseline to 20 minutes.

Cohort studies

Polosa et al conducted a proof-of-concept study to monitor changes in the smoking habits
of a group of regular smokers in Italy, focusing on smoking reduction and smoking
abstinence (Polosa et al., 2011). Eligible participants were followed up prospectively for 6
months. The study reported that in 13 of the total 40 (32.5%) participants, the use of
cigarette per day was reduced by 50% at the end of the study (P= 0.001). A reduction of
80% in the number of cigarettes smoked was observed in 5 of the 40 participants (12.5%,
P= 0.043).

A similar proof-of-concept study was conducted by Caponnetto et al to monitor
modifications in the smoking habits of a group of regular smokers with schizophrenia
experimenting a popular brand of e-cigs (Caponnetto, Auditore, Russo, Cappello, & Polosa,
2013). The study participants were followed up prospectively for 12 months. The results
showed a reduction of 50% in the number of cigarette per day in 7 of the14 participants
and the median value of 30 cigarettes per day decreased significantly to 15 cigarettes per
day (P =0.018). Additionally, sustained smoking abstinence at week 52 was observed in 2
of the 14 (14.3%) participants.

Farsalinos et al conducted a study to examine the profile and e-cig use patterns in a specific
group of past cigarette smokers who managed to completely substitute smoking with e-cig
use without using any other aid (Farsalinos, Romagna, Tsiapras, Kyrzopoulos, & Voudris,
2013). The study focused on evaluating nicotine levels used, reported side effects and
benefits, and the dependency potential of e-cigs compared with tobacco cigarettes. The
study reported that a significant proportion (42%) of the participants quit smoking during
the first month of using e-cigs. Most participants reported increasing the nicotine
concentration in their e-cigs in order to achieve complete substitution of smoking. More
than 80% of e-cig users were reported to quit smoking cigarettes by using nicotine levels
higher than 15 mg/mL.

Polosa et al investigated long-term efficacy of the e-cigs as a smoking-cessation tool in a
cohort of current smokers followed up to 24 months (Polosa et al., 2014). The prospective
observational study evaluated smoking reduction and abstinence by measuring >50 %
reduction in the number of cig/day from baseline, >80 % reduction in the number of
cig/day from baseline, and complete abstinence from smoking. The outcomes were
measured at the baseline, 6 months, 18 months and 24 months. The results showed a
significant overall 80 % reduction in median cig/day use from 25 to 4 cigarette by the end
of the study. Sustained 50 % reduction in the number of cig/day at 24 months was seen in
27.5 % subjects. There were 12.5 % quitters by the end of the study. Overall, combined
sustained 50 % reduction and smoking abstinence was seen in 40 % participants at 24
months, with a median of 24.5 cig/day decreasing significantly to 4 cig/day (p<0.001).

Another study conducted by Rigotti et al described the prevalence of current e-cig use
among adults who were admitted to nine acute-care hospitals in five geographically
dispersed U.S. cities (Birmingham, AL; Boston, MA; Kansas City, KS; New York, NY; and
Portland, OR) over 3.5 years, from July 2010 to December 2013 (Rigotti et al., 2014). The
study evaluated the association between self-report of having used one or more e-cigs in
the 30 days before the hospital admission and covariates including enrollment date, age,
sex, race/ethnicity, marital status, educational attainment, health insurance, type of
admission (emergency room vs. other), number of cigarettes per day before admission, and
whether the smoker planned to quit smoking after discharge. The results showed that
overall 14% of all patients (n=4660) admitted between July 2010 and December 2013
reported having used an e-cig in the 30 days prior to their hospital admission. Out of all the
covariates, e-cig use significantly varied by the patient characteristics of age,
race/ethnicity, education and cigarettes smoked per day. The results also showed that the
prevalence of e-cig use significantly increased over time, from 1.1% in 2010, to 10.3% in
2011, to 10.2% in 2012, and 18.4% in 2013 (p < .0001). Younger smokers (<45 years),
heavier smokers (≥10 cigarettes/day), and those with more education (high school diploma
or more) were more likely to have used an e-cigarette in the 30 days before hospital
admission, controlling for other factors.

Physiological studies

Vansickel et al conducted a study to characterize e-cig users' nicotine and CO exposure,
cardiovascular response, and ratings of nicotine abstinence symptom suppression

(Vansickel, Cobb, Weaver, & Eissenberg, 2010). The study involved 32 tobacco cigarette
smokers and compared the effect of two e-cig brands with own brand cigarettes and
placebo smoking (i.e., puffing on an unlit cigarette). The results of this acute study
suggested that two 10-puff bouts with the e-cigs exposed users to no significantly
measurable nicotine or CO and did not increase heart rate. The results also showed that
neither of the e-cig exposed users to measurable levels of nicotine or CO, although both
suppressed nicotine/tobacco abstinence symptom ratings.

Another study looking at the cardiovascular effects was conducted by Eissenberg et al and
it examined how two brands of e-cigs influenced plasma nicotine levels, heart rate and
cigarette craving in cigarette smokers, and compared these effects to those produced by
smokers’ usual brand of cigarettes (Eissenberg, 2010). The study recruited 16 naive e-cig
users who used either their own brand cigarettes, sham smoking (puffing an unlit
cigarette), or two different brands of e-cigs. The results of the study showed that relative to
tobacco cigarette, 10 puffs from either of the branded e-cigs delivered little to no nicotine
and suppressed craving less effectively.

Vansickel et al conducted a second study to investigate an initial abuse liability assessment
of an e-cig brand current regular cigarette smokers (Vansickel, Weaver, & Eissenberg,
2012). To accomplish this, the nicotine delivery profile, subjective and cardiovascular
effects of an e-cig were examined following puffs of regular cigarettes and bouts of the ecigs. Their plasma nicotine concentration, heart rate and subjective effects were measured.
It was observed that tobacco abstinence symptom suppression and increased product

acceptability ratings were associated with e-cig. In terms of heart rate, there was an
insignificant increase observed from a pre-administration average of 67.5 beats per minute
to 75 beats per minute, 5 minutes after the first e-cig bout. No effect of e-cig administration
was observed for systolic or diastolic pressure.

Flouris et al conducted a study to assess the acute impact of active and passive e-cigarette
smoking on serum cotinine and lung function, as compared to active and passive tobacco
cigarette smoking (Flouris et al., 2012). Fifteen current and fifteen never-smokers were
asked to undergo a control session, an active tobacco cigarette smoking session and an
active e-cig smoking session and their serum cotinine, lung function, exhaled carbon
monoxide(CO)and nitric oxide were assessed at the baseline, immediately post and 1 hour
post exposure of the sessions. The results showed a statistically significant linear
association between the serum cotinine levels observed immediately after and 1 hour after
the active tobacco and active e-cig sessions. Further, no statistical difference in the lung
function data was observed within each individual time point (i.e. baseline, immediately
post and 1 h post-exposure), in both groups. In the active control group, no significant
fluctuations were observed in the lung function and serum cotinine concentration. In
contrast, the lung function and CO levels changed significantly across time during the active
tobacco session. During the active e-cog session, cotinine was found to be fluctuated
significantly but no significant effect was observed in lung function and exhaled CO.

Another study to assess the physiological impact of e-cig was conducted by Farsanilos et al
(Farsalinos, Tsiapras, Kyrzopoulos, Savvopoulou, & Voudris, 2014). They evaluated the

effects of e-cig use on cardiac function, more specifically to investigate the acute effects of
using an e-cig for 7 minutes on hemodynamics parameters and myocardial function,
compared to the effects of smoking a tobacco cigarette. The study population consisted of
current smokers who were smoking for at least 5 years and were consuming at least 15
cigarettes per day and e-cig users who had quit smoking and were using e-cigs for at least 1
month. The results showed that after-use values of systolic BP, heart rate and pressure rate
were elevated in the smoker group but not in the e-cig group. In contrast, diastolic BP
increased almost equally in both groups.

Vardavas et al conducted a study to investigate whether using an e-cigarette for short
period of time could affect respiratory mechanics, using the experimental vs control group
study design (Vardavas et al., 2012). The study population was composed of 30 adults
recruited from a community setting in Athens, Greece. All subjects were current smokers
with a minimum pack-year index of 5. The results showed that with regards to pulmonary
oxidative stress, exhaled nitric oxide within the experimental group decreased by 16%
after the use of an e-cig, whereas it remained unchanged within the control group.
According to the study, decrease in exhaled nitric oxide results in respiratory impedance
and respiratory flow resistance (similar to cigarette use). The results also showed that the
lung airways impedance increased significantly in the experimental group whereas no
differences were noted among control group participants. After controlling for subject’s
baseline’s responses, the peripheral flow resistance was found to increase significantly
after use of the e-cigs.

Tzatzarakis, et al published their research in the abstracts of the 49th Congress of the
European Societies of Toxicology (EUROTOX) (Tzatzarakis, Tsitoglou, & Chorti, 2013). The
research was conducted to examine the acute and short term impact of active and passive
tobacco and e-cig smoking on inflammatory markers. Ten smokers and 10 never-smokers
completed the repeated measures controlled study. Smokers underwent a control session,
an active tobacco cigarette smoking session, and an active e-cig smoking session. Neversmokers underwent a control session, a passive tobacco cigarette smoking session, and a
passive e-cigarette smoking session. Several smoking-related biomarkers including
Interleukins (IL) 1 alpha, 1 beta, 2, 4, 6, 8, and 10 as well as vascular endothelial growth
factor, tumour necrosis factor alpha (TNFa), monocyte chemotactic protein-1, and
epidermal growth factor (EGF) were assessed at baseline, immediately following
smoking/control, and one hour thereafter. The results showed that neither a brief session
of active e-cig smoking nor a 1 hour passive e-cig smoking significantly affected the
assessed inflammatory markers. In contrast, active tobacco cigarette smoking significantly
increased IL2 and EGF immediately after smoking. Also, passive tobacco cigarette smoking
increased TNFa immediately after the smoking exposure.

Gaps in literature
Despite the increasing popularity of e-cigs worldwide, not much research has been done
regarding the long term effects of e-cigs on the smoking behavior of the current smoking
population. Most of the literature deals with survey studies, soliciting personal views on
vaping, studies analyzing potential toxins and contaminants in e-cig cartridges, reports
profiling nicotine content, delivery, and pharmacokinetics and very few clinical and
physiological studies investigating the effects of acute vaping. Till today, only one research
protocol could be found which aimed to evaluate the long-term adherence to e-cigs and the
long term efficacy of e-cigarettes in reducing and/or quitting traditional cigarette smoking.
However, the protocol plans to follow up subjects for 5 years and the results will most
likely not be out before 2018 (Manzoli et al., 2013).
None of the studies mentioned above have tried to estimate or quantify the long term
effects of e-cigs in a smoking or a non-smoking population. Most of the studies followed a
cross-sectional survey design and used a snapshot of e-cig users at one point in time. Some
studies observed the e-cig users for 6 months or maximum for 12 months to identify the
effects of cessation. Based on the short term or cross sectional study designs, most of these
studies suggest that using e-cigs or vaping could be used as a possible harm reduction tool.
However, to trust e-cigs as a smoking-cessation agent, we need to have more
comprehensive research evidence to make informed decisions. It is a well-known fact that
smoking is a long term and a highly dynamic habit. It will be safe to say that if a person who
is abstinence today, may start using e-cig tomorrow and then switch to regular cigarette in
future. Keeping that in mind, it is important identify different behavior scenarios to model

the long term effects of e-cig in a population. Using the evidence from currently available
literature, it will be interesting to predict the long term net effects of e-cigs.

Study Objectives

The primary objective of this study was to construct a Discrete Event Simulation system to
model the behavior and pattern of e-cig use among different smoking groups of the US
smoking population. The model was built and validated using the e-cig use behavior
information available in the published literature and by seeking expert opinion from the
field of Tobacco Regulatory Health Science. The secondary objective of this study was to
run the simulation model to estimate the long term prevalence of e-cig use in different
groups of the US smoking population.

Chapter 3

Methods

Overview
The primary purpose of this study was to develop a simulation model to simulate e-cig use
behavior pattern of current smokers, former smokers and never smokers for fifteen years.
We chose to use the technique of Discrete Event Simulation (DES) to model the e-cig use.
The principles of good research practices for modeling studies outlined by the ISPOR task
force (Karnon et al., 2012) were followed as closely as possible to build the model. The
model consisted of current, former and never smokers whose behavior was simulated,
based on existing data available in published literature. The model included the population
attributes and the list of events that occurred over the simulated time. The states or events
were continuously updated through the model simulation. The uncertainty around the
literature estimates was accounted by using stochastic simulation over deterministic
simulation.

What is simulation modeling?
The ISPOR task force put together a report for good research practices in modeling studies
in health care evaluation in 2012 (Karnon et al., 2012). It defined modeling as “a logical
mathematical framework that permits the integration of facts and values, which in turn link
these data to outcomes that are of interest to health care decision makers.” A generalized
version of the definition summarizes simulation modeling as a computerized version of the
system which is run over time to study the implications of the defined interactions among
the input parameters (Weinstein et al., 2003). It helps us accurately reflect the randomness
and interdependence of behavior and outcomes present in reality with available data and
resources. Using simulation, we can predict the future outcomes by including time related
events and probability distributions into the modeling framework as they occur in real life
to obtain accurate estimates (Briggs & Sculpher, 2006; Weinstein et al., 2003).

Simulation Modeling Applications in Healthcare

Simulation modelling approaches are now widely used to assess new health care
technologies, simulate disease or treatment pathways or simulate health behaviors.
Generally, the modeling is needed to study consequences of any event or intervention,
beyond the direct application of observed data (Barton, Bryan, & Robinson, 2004). In
research, simulation modeling generally comprises of mathematical equations and analytic
methodology that account for events that occur over time (Gold, Siegel, Russell, &
Weinstein, 1996). This type of modeling differs from statistical models such as regression
models by allowing a combination of information from a variety of sources or synthesize

data for the purpose of making a decision (Barton et al., 2004). Simulation modeling can
also be used in conditions where cost and effectiveness parameters are compared beyond
the data observed in a clinical trial, intermediate clinical end-points are linked to final
health outcomes, extrapolation of the results obtained in one clinical setting to other,
making comparisons of alternative competing interventions where direct comparisons
have not been made in clinical trials or guiding policy decisions in absence of real data
(Buxton et al., 1997).

As the ISPOR definition mentioned above, simulation models structures are made up of
logical framework and mathematical equations which uses the best available information
about the system being studied, the outcomes of interest, and the risks and probabilities
affecting each action (Stahl, 2008). Incorporating this information into the model structure
helps in generating evidence for or against our hypotheses, and help researchers
understand the nature of the problem under study. We also use simulation models to aid
our decision making by helping us make decisions under conditions of uncertainty. We can
use it to evaluate the outcomes of different strategies, to explore the consequences of
changes to the system and to predict how the behavior of a system with change in time.

Model Selection Process

The selection of an appropriate modelling approach is an integral step for the question
being considered. It is represented as a flowchart in figure 1.

Modeling question

Is interaction
between individuals
important?

Yes

Is individual level
modeling needed?

No

Can patient pathways be
adequately represented
and manageable by
decision tree branches?

Yes

Yes

Decision Tree

No

Is history important in
deciding the progress
of individual in the
model?

Yes
Discrete event simulation

No

Can Markov model be
built without needing
an excessive number
of states?

Yes
Markov model

Figure 1. Model selection flowchart (Barton et al., 2004)

Interaction or no interaction
The selection of the appropriate model for modeling a health care intervention should be
made along the lines shown in Figure 1. As mentioned above, the initial consideration is
whether the individuals in the model may be regarded as independent or not. When
interaction is not an important issue then the choice is between decision trees, or Markov
models. Where interaction is a significant issue in modelling, models such as DES are
required.

Cohort or individual
The second important aspect in the model selection process the nature of the object that is
to be modeled and conceptualizing what happens to those objects. The objects can either
be modeled as a population (cohort or aggregate modeling) or as individuals in the
population (individual level simulation) (Brennan, Chick, & Davies, 2006). With respect to
conceptualizations, the problem can be represented as a series of states that the objects can
be in, or it can be represented as events the objects can experience (Brennan et al., 2006;
Stahl, 2008).

There are two major concerns with a cohort approach. Firstly, the determination of
proportion of population at each relevant time point. That proportion is dependent on the
risk the population is exposed to, and that risk is affected by treatment the population is
subject to. However in reality, the risk will also depend on patient characteristics, such as
age, sex, smoking, and other risk factors. Hence, it is important to characterize the
population and examine these factors individually.

Secondly, the transition from one state to another is not random. People who are at higher
risk, tend to move from better to worse state earlier than the rest. However, it is difficult to
characterize these patients in terms of features that may be determinants of further risk. If
the future risk is dependent on the duration of the time spent in the previous state, the
estimates will be inaccurate given that the arriving populations mix into a single group and
do not retain any memory of when they became sick (Caro, Moller, & Getsios, 2010).

All the problems listed above in the cohort approach are readily solved by modeling
individuals instead of the entire population in the aggregate. For each individual, the risk
can be computed based on their characteristics, the risks can be easily updated over time,
and can be recalculated based on changing history of an individual. Individual level
modeling give us the freedom from restriction to analyze population as homogeneous
groups with equal risks for everyone.

State versus Event
In a state-transition model, such as Markov models, the system is conceptualized as a series
of interrelated that the population may be in. These snapshots occur at fixed, discrete time
points called cycles. Trying to represent conditions with large number of states leads to
different combinations of all possible outcomes, which may result in inaccuracies.

The most common types of healthcare models that do not involve interaction are decision
trees and Markov models (Karnon & Brown, 1998).

Decision Trees
The Decision Tree has the simplest structure. All possible patient pathways are shown
explicitly on decision tree branches, with associated probabilities and outcome measures. If
the time frame is short and if the nature of patients’ outcome does not differ across
strategies, a simple decision tree is an appropriate choice. Decision trees are usually
constructed with a single decision node at the root of the tree, which then grows into a set
of linked probability branches, one for each alternative. Although decision trees are simpler
to understand and analyze, there is a limit to the manageable size of a tree. In case of a
complex problems, such as a situation where the issue of interest is the survival time, using
a decision tree becomes a cumbersome approach. To avoid an infinite number of branches
in the tree, it is necessary to consider a different approach to model survival time with a
different ranges.

Markov Models
Markov models are increasingly being used in complex healthcare problems. Their main
advantage is the easy representation of recurrent events, but like decision trees they do not
allow for interaction between individuals. Also, the transition probability depends only on
the state in which the patient is at the start of the cycle. This is known as the Markov
assumption. The Markov assumption does not allow the transition probability to depend
either on the time a patient has spent in a given state, or the patient’s previous history
before entering that state (Briggs & Sculpher, 1998). Markov models thus assume that
patients in a given state can be treated as homogeneous groups and this homogeneity

assumption is inherent in Markov models. For any given alternative, the proportion of
patients in each state can be calculated sequentially for each time cycle over a period of
simulated time. Costs are then accumulated according to the number of patients in a given
state in each cycle. Different policies may be tested by changing the costs and transition
probabilities.

Models that account for interaction between individuals

Discrete Event Simulation
DES accounts for interaction between individuals. Also, when the outcome depends on the
history of the patient or the continuous update of patient’s characteristics, models such as
DES are required. DES works at an individual level and allows full representation of each
individual’s history and the interaction between specific individuals. It can accommodate a
more complex structure than Decision Trees and Markov models, and can still remain
manageable in size.

DES provides the luxury of overcoming the homogeneity assumptions by attaching
attributes to the individuals within a model. The transition probabilities can be made to
vary according to these attributes in any way that is desired. Furthermore, attributes can
be updated while the model is running. Another advantage of DES is that it allows the
patient to remain in a given state for a variable length of time, unlike the fixed states of
Markov models. Also, DES uses stochastic models that include probabilistic sensitivity
analyses to quantify the uncertainties caused due to variability in parameters whereas

deterministic models are mathematical models where outcomes are precisely determined
through known relationships among states and events, without any room for random
variation. Conducting probabilistic sensitivity analyses in stochastic models also allows
some amount of generalizability over different geographical and demographic settings.
In a DES, the experience of individuals is modeled over time in terms of the events that
occur and the consequences of those events. Many of the limitations and inaccuracies of
Markov models and decision trees are easily avoided with DES.

Another big advantage of DES over cohort-based models is that they can work relatively
more efficiently with limited data availability. The quality of model is highly dependent on
the data which is incorporated into it. In case of limited individual level data availability, a
DES model provides a great advantage because the inadequacy of the data is not built into
the structure of the model (Caro et al., 2010). The simulation can be designed to properly
reflect the problem and carry out exploratory analyses with the limited data and make
predictions. It can then incorporate additional data when it becomes available (Caro et al.,
2010). In our case, simulation will be useful as long term observational data pertaining to
e-cig use is not available yet. It will help us better understand and predict the vaping
behavior (real or hypothetical) that we are trying to examine.

The differences between Decision Trees, Markov models and DES are outlined in table 1
below:

Features

Decision Trees

Markov Models

Discrete Event Simulation

Time horizon

Short

Short and long

Lifetime behavior

# of events modeled

Small

Relatively higher

High number of events

Memory feature (Different
risk factors over time)

No

No

Accounts for risk changes

Probabilistic sensitivity
analysis

Difficult

Difficult

Inherent in the model

Data requirement

Not good for limited
data

Not good for
limited data

Simulate large number of
subjects with unique
characteristics

Accounts for interactions
between individuals

No

No

Yes

Update of model
population

No

No

Yes

Computational
requirements

Simple (Microsoft
Excel)

Simple (Microsoft
Excel)

Special software programs

Table 1. Main differences between Decision trees, Markov models and DES

Discrete Event Simulation and its components

The working structure of a DES closely replicates the course outlined in ﬁgure2.
Initialize




Set simulation clock
Initialize system state
Initialize event list

Determine next event



End run

Arrival of the entity
Occurrence of an event

Advance clock

Process event




Compute final
estimates
Generate reports





Update system state
Update counters
Generate future event

Figure 2. Flow diagram of the computation process for a discrete event simulation (Caro et al., 2010).

The model starts by setting the simulation clock to zero. The initial state is set by the user
based on the system being modeled and incorporating the baseline characteristics of the

model population. Next step is to list out all the relevant events using the logical and
mathematical framework of the system. This will drive the flow of the model population
and decide the change in current and future states of the model. Once the initialization step
is over and the model is made to run, based on the individual’s characteristics and the way
it is programmed, it determines which event will the individual will go to next. Accordingly,
the system jumps to the next event by bringing the individual to that particular state and
advancing the simulation model clock, which in turn records the time at which the event
took place. Once the event is processed in the system, the change in states of the individuals
and the system as a whole is recorded and the individual characteristics are updated. Based
on the updated characteristics, the future states in the path of the individual is determined.
This process is repeated until all the individuals are made to go through the entire cycle or
until the pre-set simulation time period ends. After the simulation has ended, final reports
are generated showing the estimated outcomes of the simulation.

The fundamental components of the DES technique are described below:
1) Entities
A central component of DES is the entity. Entities are the items that flow through the
simulation, smokers in our case. Smokers have attributes (e.g. age, sex, race, smoking
history), with each individual having a speciﬁc value for each characteristic. These values
are defined at the start of the simulation and are updated as events take places such as age
increases, initiating e-cig use, or quit attempts. These updates can happen at particular
points in time. The model update is decided on the basis of the structure of the problem.

2) Events
The second major element of the simulation is the events that drive the entities. An event
can be deﬁned as anything that happens during the simulation. Thus, it can be the
occurrence of a quit attempt, initiation of e-cig, relapse or just aging in the model. Events
can happen in any logical sequence and even simultaneously. They can recur if that
happens in reality. Events change the course of individuals’ experience by inﬂuencing their
attributes and occurrence of future events with no restriction on memory. For example, the
initiating of e-cig can depend on previous use but can also be altered by making a quit
attempt in future. The rates at which events occur can take any functional form supported
by the data or assumptions. They can be dependent on any attributes or variables and
these functions can change over time as appropriate.

3) Time
The third important component of a DES is time. A simulation clock keeps track of the
passage of time in the model. This permits the modeler to clearly signal the start and end of
the simulation and to create internal time periods such as the length of staying in a
particular state. By making time explicit, a DES allows more ﬂexibility than Markov models
and Decision trees. Time moves continuously and the units can be minutes, days, months or
whatever is convenient. However, since the progression of simulation depends on events,
the simulation clock is advanced to the time when the next event will occur.

4) Means of Execution
The ﬁnal component is the means to execute the simulation, following a desired logic and
carrying out all the calculations. The execution begins by formulating the question in detail,
providing a description of the system that is to be modelled, specifying the details that
pertain to the condition in question. Following that, the model is designed conceptually in
the form of an influence diagram. Once the concept has been validated with help from
relevant experts, data are fit to the model.

5) Actual simulation
Once the model is coded in software and debugged, the analysis in a DES proceeds by
specifying the initial system conditions (i.e. starting values for all attributes and variables)
and simulation settings (e.g. duration, time units, number of replications). The software
then carries out the simulation by applying the logic to each entity (patient) using random
numbers to obtain specific values from assigned distributions and determine whether
probabilistic events occur at a given time to a given patient. Thus, a DES is an individual
patient, stochastic simulation (Caro et al., 2010).

As explained in the overview section of this chapter, we decided to construct a DES model
to simulate the behavior of e-cig users in the US. The description of the data sources, model
parametrization, simulation pathway and handling uncertainty is described as follows.

The E-cig model

Generating the model population
To generate the model population, we used publicly available data from the cross-sectional
National Health Interview Survey (NHIS), a nationally representative multistage household
survey of the civilian noninstitutionalized population of the United States. The National
Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC)
has conducted the NHIS annually since the 1950s to monitor the nation's health at both the
household/family level (e.g., type of living quarters, family size, and total combined family
income) and the individual level (e.g., various medical/health conditions, risk factors, and
access to care). The main objective of the NHIS is to monitor the health of the US population
through the collection and analysis of data on a broad range of health conditions. The
survey also collects current data on many demographic and socioeconomic characteristics
(NCHS, 2012).
The NHIS covers the civilian population residing in the United States at the time of the
interview. It is a cross-sectional household interview survey and the sampling plan follows
a complex, multistage probability sample that incorporates stratification, clustering, and
oversampling of some subpopulations (e.g., Black, Hispanic, and Asian) in some years (MPC,
2011; NCHS, 2012). Because of the complex sampling design of the NHIS, sampling weights
are constructed so that each unit (survey respondent or household) can be inflated or
expanded to represent other individuals or households in the United States (NCHS, 2012).

The NHIS questionnaire contains four major components: Household, Family, Sample
Adult, and Sample Child. The Household component collects demographic information on
all of the individuals living in a particular house. The Family component collects additional
demographic information on each member from each family in the house and collects data
on topics including health status and limitations, injuries, healthcare access and utilization,
health insurance, and income and assets. The Family Core component allows the NHIS to
serve as a sampling frame for additional integrated surveys as and when needed. From
each family in the NHIS, one sample adult and one sample child are randomly selected and
information on each is collected with the Sample Adult Core and the Sample Child Core
questionnaires. Because some health issues are different for children and adults, these two
questionnaires differ in some items but both collect basic information on health status,
health care services, and health behaviors. Its protocol and administration have been
approved by the NCHS's Research Ethics Review Board, and all NHIS participants provide
informed consent (NCHS, 2012).
For the purpose of our model population, we pooled the data for 2011, 2012 and 2013 to
generate a recent national estimate of the US population with specific demographic and
smoking-related characteristics. Each data file contained household, family, and person
record identifiers that made merging the data files possible. Once the data files were sorted
by the household, family, and person record identifiers (coded as HHX, FMX and FPX in
NHIS, respectively), the Household, Person, and Sample Child data files were merged, for
each of the three years. Variable names were changed from one year to another when
required. The data across the years were combined or concatenated to increase the
number of observations or respondents and thus increase the precision of estimates. The

three years’ worth of merged data files joined one after the other (concatenation). New
weights were constructed to adjust for combining data years. For three years of data, the
new weights were calculated by dividing the original weights by 3 to give the final weight
of every individual in the sample.
The pooled dataset had 86,402 individuals who had complete information on their
demographic characteristics and smoking behavior. We classified a respondent's cigarette
smoking behavior by his/her answers to questions about cigarette smoking status and
smoking cessation attempts based on an existing NHIS recoded variable with six response
levels: current smoker, recent former smoker, and never smoker. Respondents that
reported having smoked at least 100 cigarettes in their entire life and were currently
smoking every day or some days at the time of interview, were classified as current
smokers (CS). Respondents reported smoking at least 100 cigarettes during their lifetime
but currently did not smoke at least for the past 12 months, were classified as former
smokers (FS). FS were further classified into recent former smokers or late former
smokers. Recent former smokers were those former smokers who had stopped smoking
less than 12 months ago. Late former smokers were those former smokers who had
stopped smoking over a year ago.

Respondents reported not having smoked at least 100 cigarettes in their life and were not
currently smoking for the past 12 months, were classified as never smokers (NS). This
method of smokers’ classification has been recommended by NCHS and is used in earlier
studies done on smoking population (Mehta & Preston, 2012).

Descriptive analyses was run on the sample to calculate the frequency distribution of
population demographic and smoking characteristics. The demographic categories
included age (<21, 21-35, 36-50, 51-65, >65), gender (male, female), race (white, black,
other), and education level (less than high school, high school, college). The smokingrelated categories included years of regular smoking (for current smokers), at least one
quit attempt in the past 12 months (for current smokers) and nicotine dependence score
(for current smokers). The information on nicotine dependence had to be utilized from a
different source. We used the estimates of a matched sample, from a web based survey on
current and former smokers in the US (Yeomans et al., 2011).
Probability estimates related to e-cig use
The probabilities of current e-cig use associated with different demographic and smoking
characteristics, among different smoking categories of the US population were derived
from the prevalence estimates published in several cross-sectional and longitudinal e-cig
studies done in the US.
The e-cig prevalence estimates associated with age, gender, race, education level for
current, former and never smokers were utilized from the Knowledge Networks survey
data, which was commissioned by the University of California, San Diego (Zhu et al., 2013).
The survey collected information on smoking history and cigarette use, perceptions about
different tobacco products and quitting aids, attitudes toward tobacco control efforts, and
beliefs and ideation about the process of quitting smoking. The study sampled the smokers,
former smokers and never smokers from the panel in a way such that the three smoking
status groups were approximately equal in size. The final survey sample consisted of 3,111

current smokers, 3,676 former smokers and 3,254 never smokers. Following the same
classification as our NHIS sample, current smokers (CS) were defined as those who had
smoked at least 100 cigarettes in their lifetime and were still smoking some days or every
day at the time of survey administration. Former smokers were defined as smokers who
smoked at least 100 cigarettes in their lifetime and were not smoking at the time of survey
administration. Former smokers were further classified into recent former smokers (RFS)
and late former smokers (LFS). Former smokers were classified as RFS if they smoked their
last cigarette within the time period of 1 year or less, and as LFS if they smoked their last
cigarette over 1 year ago. Never smokers (NS) were defined as those who had not smoked
100 cigarettes in their lifetime (Zhu et al., 2013).

Use of e-cigs was also assessed in multiple questions. First, respondents were asked if they
had ever heard of e-cigs. Next, those who had heard of e-cigs were asked if they had ever
tried an e-cig. Those who answered yes were considered ever users. Ever users were also
asked if they had used e-cig multiple times in the last 30 days. Those who answered yes,
were considered current e-cig users (Zhu et al., 2013).

Along with the prevalence estimates associated with demographic characteristics, the
Knowledge Networks Panel survey data also provided related standard errors and 95%
confidence intervals which were used to carry out sensitivity analyses for the simulation
model. We did not use the prevalence estimate for ever e-cig users as published studies
have indicated that ‘ever use’ is not the accurate measure of e-cig prevalence (Adkison et
al., 2013; Bell & Keane, 2012). Mostly, ever users have been known to try e-cig once and not

continue after that. Also, we wanted to use a conservative estimate in our simulation model
to predict the outcomes. Hence, current e-cig use estimates were chosen over ever e-cig
use.

Zhu et al did not report the prevalence associated with e-cig users below 18 years. Since
the age group of 6-18 years has been associated with a high use of e-cig in the US (Agaku et
al., 2014), we used another study to obtain prevalence estimates of age category 6-20
years. The study analyzed a sample of 3,912 high school and middle school students of
current and recent former cigarette smokers and e-cig users (Camenga et al., 2014). The
students were attending high schools in Connecticut and New York and were asked similar
questions as in the Knowledge Networks survey.

For the probability associated with making a quit attempt, we used estimates from the
Legacy Longitudinal Smoker Cohort (LLSC) survey data (Pearson et al., 2012). The LLSC
collected data on a large cohort of current smokers and recent former smokers (n= 5616)
living in the US, and was used to obtain demographic and point estimates for awareness,
use, and harm perceptions associated with e-cigs.

The e-cig use associated with the nicotine dependence score and cigarette per day use,
were derived from estimates obtained from the International Tobacco Control Four
Country Survey (ITC-4) data, conducted between 2002 and 2011 (Kasza et al., 2014). The
survey population consisted of 6,110 adult smokers in the US, Canada, UK and Australia
and it examined the demographic and smoking-related predictors of use of unconventional

tobacco products (i.e., other smoked tobacco products, smokeless tobacco products,
unconventional cigarettes, and e-cigs). We used the estimates reported for the US
population. The prevalence estimates along with the source for current, recent former, late
former and never smokers are summarized in tables 6, 7, 8 and, 9 respectively, in the
results section.

Model parametrization

The model was structured in terms of the specific events that individuals experience over
the course of the simulation. The events and the attributes assigned to the model
population were chosen after reviewing the e-cig literature and choosing the variables
which had statistically and practically significant association with the use of e-cig among
current, former and never smokers. Most studies indicated that age, gender, race, education
level, years of smoking, past quit attempts, and nicotine dependence showed a significant
association with the use of e-cig among current cigarette smokers (Kalkhoran, Grana,
Neilands, & Ling, 2015; Kasza et al., 2014; King et al., 2013; McMillen, Gottlieb, Shaefer,
Winickoff, & Klein, 2014). Accordingly, each individual was assigned a set of unique
attributes which were corresponding to their baseline characteristics at the start of the
simulation. These attributes or characteristics, were updated throughout the simulation,
depending on the subject’s course through the model. The set of events in the simulation
correspond closely to the behavior of e-cig users when they switch to e-cigs.

At the beginning, 100,000 smokers were generated by using the “Create” module from the
Arena toolbar. The smokers were created and an exponential distribution was assigned to
their arrival in the system. Once the model population was generated, the next step was to
send them into one of the four branches; CS, RFS, LFS, and NS. The percent of people sent
into each depended on the real live distribution of smokers obtained from the NHIS data.
Next, the smokers were assigned baseline attributes using the “Assign” module. We
assigned age, gender, race, education level, nicotine dependence, years of smoking,

cigarette per day use, and past quit attempts to each initial smoker. We then recorded each
smoker's yearly progress based on these assigned characteristics.
Age
The age assignment was done using the frequency distribution from the NHIS survey. The
attribute “Age” was categorized into 5 age groups, which matched the data available for ecig use. A continuous probability distribution was assigned to the Age attribute.
Additionally, an original age attribute “AgeOrig” was assigned in the simulation to keep the
track of the smokers’ increasing age within the system. Finally, another attribute “Age
Group” was assigned based on current age in the model.
Gender
Similar to the age assignment, the “Gender” attribute was assigned using the frequency
distribution from the NHIS survey. The assignment was done at two levels; 1-Male, 2Female, and a discrete probability distribution was assigned to this attribute.
Race
The smokers’ race was assigned as a 3-level attribute named “Race”. Derived from the NHIS
sample, level 1 was for “white”, 2 for “black” and 3 for “others”. The Race categorization
was done to match the e-cig use data. Similar to the Gender attribute, Race was assigned a
discrete distribution.

Education
The education level was assigned as a 3-level attribute named “Education”. Derived from
the NHIS sample, level 1 was for smokers who had did not have a high school diploma, 2 for
smokers who had at least a high school diploma and 3 was for smokers who had at least a
college degree. The Education categorization was done to match the e-cig use data.
Education was also assigned a discrete probability distribution.
Nicotine Dependence score
The next assignment was done using the “Assign” module again and it was used to assign
the nicotine dependence score attribute “FTND score” to current smokers. The 3-level
attribute derived the values from the matched sample from the web-based survey of US
current smokers (Yeomans et al., 2011). It was assigned a discrete probability distribution.
Previous Quit attempts
The assignment of previous quit attempts was done using the distribution from the NHIS
sample. The 2-level attribute was named “PrevQuit” and it had 0 for smokers who did not
make even a single quit attempt and 1 for smokers who had attempted to quit at least once
in their life. It was assigned a discrete probability distribution. Along with the “PrevQuit”
attribute, another attribute named “CountQuitAttempt” was assigned in the system. The
original value of this attribute was assigned as “PrevQuit” and its value was supposed to
increase with every quit attempt a smokers makes in the simulation. Essentially, this step
created the history of quit attempts before the current smokers entered the simulation
model. CountQuitAttempt attribute was used to add the new quit attempts to the quit

attempts already made in the past (PrevQuit) of a current smoker, and there by changed
the individual risk associated with the quit attempts in the system.
Assigning baseline probabilities and distributions
The probability for each event in the simulation model was assigned using the “Variable”
module. A specific probability within each level of attribute, for every attribute was
assigned which was responsible for events experienced by that individual smokers through
the simulation. The probabilities were derived from the e-cig prevalence estimates
discussed above.
Two specific distributions were assigned to the probabilities in the model, Continuous and
Discrete. The Continuous distribution in Arena returns a sample from a user-defined
continuous distribution, which in this case was the age distribution. Pairs of cumulative
probabilities and associated values are specified, and then the sample returned has a real
number between associated values and with corresponding cumulative probabilities. The
continuous empirical distribution is often used to incorporate actual data for continuous
random variables directly into the model.
The Discrete function in Arena returns a sample from a user-defined discrete probability
distribution. The distribution is defined by the set of n possible discrete values that can be
returned by the function and the cumulative probabilities. In our study, model inputs such
as gender (1, 2), race (1, 2, 3), or education level (1, 2, 3) had discrete distribution. The
discrete empirical distribution is often used to incorporate discrete empirical data directly
into the model.

Simulation Pathway
This section presents the events that determine whether or not simulated smokers will
become an e-cig user or not. For current smokers, these events were:


Using e-cig



Making a quit attempt



Relapse



Quitting



Ageing



Leaving the model

Once the smoker entered into the model, he/she was assigned the baseline attributes,
associated probabilities and the corresponding probability distributions. After that, the
smokers moved ahead and were given a choice to initiate using e-cig. The decision to use or
not use came from the probability equations discussed below.
If the smoker decided to start using e-cig, he or she was given a chance to quit using e-cig
within that same year. Around 48% made a quit attempt after using e-cig once and did not
use it again. However, 52% continued using e-cig. This estimate was used from the study
conducted by Kasza et al where the smokers who became e-cig users were asked after 1
year if they had made any attempts to stop smoking after using e-cig (Kasza et al., 2014).
Smokers who made a quit attempt the same year, were evaluated if they made a relapse to
using e-cig within the same year. Based on the same study, 9% smokers who attempted a
quit attempt did not make a relapse and stayed a quitter (Kasza et al., 2014). These quitter

were then assigned the status of “Former smoker” and their risk of e-cig use also were
changed accordingly. Smokers who continued using e-cigs (relapse) were allowed to
remain the in the loop and age in the simulation process. Next year, these smokers were
made to pass through quit attempt module again to see if they made a quit attempt next
year. Smokers who made a relapse were evaluated for the number of quit attempts and
their age.
With each failed quit attempt, the probability of using the e-cig increased by 13% according
to the literature (Pearson et al., 2012). We factored this scenario by recording the new quit
attempts made after initiating the e-cig to the “CountQuit” attribute. That way, the new quit
attempts were added to the history of previous quit attempts, and accordingly changed the
overall probability of using the e-cig again in the simulation model. We did not want the
probability to cross over 100% with several quit attempts, so we limited the number of quit
attempts to 4. Anyone who made 4 quit attempts in the model, was counted as a regular ecig user and allowed to exit the model.
Finally, smokers who did not initiate e-cig in the first year were allowed to age and
assigned two new risks for initiating e-cig next year. First, as they aged a new risk of using
e-cig was assigned based on their new age. Second, after 7 years into the simulation, every
year the overall risk was made to reduce by 1% of the preceding year. We did this because
we assumed that the initiating probability of e-cig will reduce in future due to variety of
reasons ranging from new policies or regulations to the launch of new unconventional
tobacco products. Also, since e-cig has been launched fairly recently, currently it is not
regulated by any agency. However, in a few years, perhaps the FDA will control the sale of

e-cigs to young adults, or another unconventional tobacco product will be launched, or the
consumer will have enough information about e-cig to make a decision, so its prevalence
will wane down (Foulds et al., 2011). Hence, we factored this in by reducing the overall risk
each subsequent year. Please see figure 3 for the working structure of the DES model. We
used the risk reduction of 1% from a recent study done to examine the potential impact of
price-related and tax-related policies on e-cigs use by assessing the own and cross-price
elasticity of demand for e-cigs (Huang, Tauras, & Chaloupka, 2014). The study reported a
10% increase in price would reduce sales of e-cigs by approximately 12% or 10%. Taking
the conservative approach, we first reduced the risk by 1% each year after the 7th year, and
then tested the impact by increasing it to 3% and 5% each year in sensitivity analyses.
Similarly, we tested the impact of timing of the policy by applying it at 5 years, 10 years and
not applying it at all.
Cumulative probability equation
The ideal way to calculate the probability of an event happening is to run a linear
regression on the model parameters to get the relationship and mutually exclusive
probabilities. According to the probability theory, events E1, E2, En are said to be mutually
exclusive if the occurrence of any one of them implies the non-occurrence of the
remaining n − 1 events. Therefore, two mutually exclusive events cannot occur at the same
time. Formally said, the intersection of each two of them is empty (the null event): A ∩ B =
0. In consequence, mutually exclusive events have the property: P(A ∩ B) = 0
(Beerenwinkel & Siebourg, 2012).

However, due to unavailability of individual level data related to e-cig, we were unable to
use mutually exclusive probabilities. Instead, we used non-mutually exclusive event
probabilities. Non-mutually exclusive events are events in which there is some overlap.
When P(A) and P(B) are added, the probability of the intersection is added twice. To
compensate for that double addition, the intersection needs to be subtracted. In other
words, the probability of one or both events occurring is denoted P(A ∪ B) and in general it
equals P(A) + P(B) – P(A ∩ B) (Beerenwinkel & Siebourg, 2012). Hence, we added all the
individual probabilities associated with e-cig use and subtracted the intersections from the
total sum.

Outcome Measures

Structural simulation of e-cig users’ behavior

One of the broader outcome of this study was to make an exploratory model which uses the
currently available literature in structurally capturing the behavior of current, former and
never smokers in terms of e-cig use. The model structure accounted for change in smoking
habits, temporary or permanent use of e-cig, quitting behavior and relapse to smoking.

E-cig prevalence among current, former and never smokers

Another important outcome of this study was to estimate the national prevalence of e-cig
use among the population of current cigarette smokers, past cigarette smokers and never
smokers, and plot the estimates against time. The prevalence was also estimated in the sub
population groups, specifically within different age groups, gender, race, and education
level. The model was run for the period of fifteen years and the prevalence was plotted
against time for each of the fifteen years.

Simulation runs

The model ran several sets of analyses to introduce the variation around the estimates.
Specifically, the model was run using populations of 100,000 current, former and never
smokers. Every simulation was for 100 replications to obtain confidence intervals when
examining changes in the smoking groups.

Calculating smoking prevalence
The prevalence was calculated using the formula below:


The average number of simulated CS, recent FS, late FS and NS who were recorded
as e-cig users at the end of the simulation, for each time period.



The size of the simulated smoking population (N=100,000) which entered the
model.



Since it is a population model, each year the number of people being born and dying
were taken care by implementing the equation:

Population t+1 = Population t + br * Population t – dr * Population t

The birth rate (br) adds to and the death rate (dr) subtracts from the population at
each point, and the rates were obtained from the US census bureau website (US
Census Bureau, 2014).



Prevalence was then calculated by dividing the average number of e-cig users
during the specified time period by the size of the simulated population.
The formula for calculating prevalence is shown below.
Prevalence=

E-cig users at the end of each time period
X 100
Size of simulated population during the same time period

Model validation

The model was validated by a variety of methods. First, the model was tested for internal
validation by using null and extreme input values to test whether they produce the
expected outputs. This helped in verifying that the mathematical equations were
calculating the correct values. Secondly, it was checked for debugging that included getting
the program code examined for syntactical errors and test of reproducibility using
equivalent input values. Debugging was performed by getting the programming code
verified by Dr. Jaime Carro (Evidera) and Dr. Jorgen Moller (Evidera), who are experts in
DES programming and have been making DES models in healthcare evaluation for over 10
years. Thirdly, the structural validity was conducted by getting the model structure
examined by experts in the area of e-cig use. It ensured that the model incorporated all the
feasible behavior scenarios in the model structure. Additionally, the model structure was
validated by comparing our model structure with other published DES models (Gestios et
al, 2013; Howard et al, 2008) which looked at cigarette smoking behavior and smoking
cessation strategies, and the scenarios applicable to smoking behavior were incorporated
in our model structure. Fourth, the model was tested for internal consistency by verifying
that the mathematical probability equations used in the model were correct based on the
probability theory and by seeking expert opinion from professionals in modeling and
systems analyses. This was done by getting model structure verified by Dr. Edward Boone
(VCU) and Marc Botteman (Pharmerit), who are experts in the area of system analysis.
They checked the flow of smokers through different branches and helped in authenticating
the output of our model.

We believe that getting our model verified by external DES and system analysis experts
also increased the face validity of the model. Face validation helped to ensure that the
model was constructed and used in accordance with the most current scientific and best
available evidence. This enhanced the credibility and the acceptance of results. Moreover,
we were able to perform limited amount of external validity which means comparing the
model’s results to actual information in the real world. It involved comparing our model’s
first year’s results with the most recent CDC reports on e-cig prevalence in the US
population. Due to data limitation, we could not perform an independent validation
whereby data used to validate comes from a source other than the one used to build the
model.
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Figure 3. Working flowchart of the model structure.

Model assumptions


The proportion of smokers using e-cigs in each sub-group was assumed as
probabilities associated with the use of e-cig.



The decision to use or not to use an e-cig each year in the model, depended only
upon their baseline demographic and smoking characteristics and associated
probabilities.



The probability associated with making a quit attempt toward e-cig were assumed
to be similar to the probability associated with quitting regular cigarette.



Smokers inside the simulation model were not all allowed to use any external
smoking cessation source such as primary or secondary smoking cessation
treatments. Also, they were assumed to be willing to try e-cig as a smoking cessation
tool.



The quit attempt made inside the simulation model was assumed to be associated
only with the use of e-cig and not because of external factors such as smoker’s
intention, health risks, or cost changes.



In never smokers, a person was assumed to not initiate using e-cig after 35 years of
age.



The nicotine dependence score derived from the matched sample of the web based
survey smokers’ profile were assumed to be the nicotine dependence score of
current smoker population created from NHIS.



The effect of e-cig policies and regulations which will come into place in future was
assumed to be 1% and was factored in the model by structuring a branch for non e-

cig users which reduced the overall probability of using e-cig by 1% each
subsequent year.


It was assumed that the smoking environment will not have any drastic change
which will affect the initiation and the use of e-cig for the next 15 years.



Smokers over 85 years were assumed to die and allowed to exit the model.



The number of maximum quit attempts a person could make in the simulation was
capped at 4.



All e-cig users were assumed to be using a nicotine containing e-cigs.
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Results

Model Population Descriptive Analyses
Demographic
attributes
Age
<21 years

N

Weighted N

Weighted %

Standard
error

60

839069

1.825

0.257

21-35 years
36-50 years

1209
1184

15951411
15583632

34.701
33.901

1.063
0.808

51-65 years
>65 years

944
376

10921864
2671325

23.760
5.811

0.898
0.449

Gender
Male
Female

2179
1594

25536741
20430560

55.554
44.445

1.089
1.089

Race
White
Black
Other

1813
944
1016

31386247
6412197
8168857

68.279
13.949
17.771

2.521
1.385
1.603

No high school
diploma

391

2958378

9.615

0.692

High school
diploma

1079

13470898

43.781

1.400

Any college

1032

14339077

46.603

1.504

Education

Table 2(a). Demographic attributes of the national sample of current cigarette smokers.

CPD (Means, SD)
Years of regular smoking
(Means, SD)
At least 1 quit attempt in past 12
months (%)

Smoking related attributes
11.87 (8.80)
27.02 (15.69)
46.97

Table 2b. Smoking related attributes of the national sample of current cigarette smokers.

Table 2(a) presents the baseline characteristics of the current cigarette smokers’
population in the US. The weighted N and the weighted percent indicate the nationally
representative sample. The age-wise distribution indicated that most of the current
smokers were in the age-group 21-35 years old (34.70%), followed by the age group of
36-50 years old (33.90%). Around 55.56% of CS were males, 68.28% white and 46.60%
had a college degree. Table 2(b) presents the distribution with respect to the smoking
related attributes. Mean (SD) cigarette per day (CPD) use and mean (SD) years of
regular smoking were found to be 11.87(8.8) and 27.02(15.69), respectively. Around
46.97% of current smokers had attempted at least 1 quit attempt in the past 12 months.

Demographic attributes

N

Weighted N

Weighted %

Standard
error

Age
<21 years

18

271816

0.515

0.163

21-35 years
36-50 years
51-65 years
>65 years

496
774
1279
1694

8135462
12341650
16893561
15089969

15.427
23.404
32.036
28.616

0.976
1.126
0.923
1.138

Gender
Male
Female

2560
1701

29172122
23560335

55.321
44.679

1.082
1.082

Race
White NH
Black NH
Other NH

2323
730
1208

41275536
3814939
7641983

78.273
7.234
14.491

1.710
0.781
0.835

Education
No high school diploma

552

3452526

10.832

0.955

High school diploma

949

11874463

37.255

1.836

Any college

1189

16546498

51.913

2.020

Table 3. Demographic attributes of the national sample of recent former cigarette smokers.

Table 3 presents the baseline characteristics of the recent former cigarette smokers’
population in the US. Most of the smokers were in the age group 51-65 years old
(32.03%) followed by smokers in the age group >65 years old (28.61%). The age group
of <21 years old had the least proportion of smokers (0.52%). Around 55.32% of recent
FS were males, 78.27% white and 51.91% had a college degree.

N

Weighted N

Weighted %

Standard
error

9

152956

0.323

0.145

359
676
1187
1630

6026529
10743499
15758480
14574125

12.753
22.734
33.347
30.841

0.924
1.108
0.898
1.229

Gender
Male
Female

2336
1525

26293298
20962291

55.640
44.359

1.030
1.030

Race
White NH
Black NH
Other NH

2124
653
1084

37248217
3347783
6659589

78.822
7.084
14.092

1.662
0.779
0.812

511
848

3202542
10604450

11.298
37.413

1.041
1.903

1074

14537169

51.288

2.017

Demographic attributes
Age
<21 years
21-35 years
36-50 years
51-65 years
>65 years

Education
No high school diploma
High school diploma
Any college

Table 4. Demographic attributes of the national sample of late former cigarette smokers.

Table 4 presents the baseline characteristics of the late former cigarette smokers’
population in the US. Similar to recent FS, most of the late FS were in the age group 5165 years old (33.35%) followed by smokers in the age group >65 years old (30.84%).
The age group of <21 years old had the least proportion of smokers (0.32%). Around
55.32% of late FS were males, 78.82% white and 51.28% had a college degree.

Demographic attributes

N

Weighted N

Weighted %

Standard
error

Age
<21 years
21-35 years
36-50 years
51-65 years
>65 years

231
2679
2574
2199
1980

3340197
35530624
37034518
27546725
17053907

2.771
29.484
30.732
22.859
14.151

0.403
0.940
0.880
0.662
0.507

Gender
Male
Female

3907
5756

50751366
69754605

42.115
57.884

0.598
0.598

Race
White NH
Black NH
Other NH

3637
2125
3901

76205275
14735580
29565116

63.237
12.228
24.534

2.208
1.090
1.249

Education
No high school diploma
High school diploma

1189
2023

7503846
24466045

11.060
36.061

0.755
1.052

2681

35875006

52.878

1.173

Any college

Table 5. Demographic attributes of the national sample of never cigarette smokers.

Table 5 presents the baseline characteristics of the never smokers’ population in the US.
Most of the NS were in the age group 36-50 years old (30.73%), followed by smokers in
the age group 21-35 years old (29.48%). The age group of <21 years old had the least
proportion of smokers (2.78%). Around 57.88% of NS were females, 63.23% white and
52.88% had a college degree.

Tables 6, 7, 8 and 9 show the results of the literature review done to obtain demographic
and smoking behavior related risks associated with the initiation of e-cig. The tables list the
assignment of probabilities associated with initiating of e-cig use, based on each level of
population attribute for current, recent former, late former and never smokers,
respectively. Along with that, the columns show the assigned probability distributions, data
source and the studies which analyzed the data and reported those estimates.

Model Input Parametrization

E-cig use
probability

Parameters
Age, years

Assigned probability
distribution

Data

Source

Continuous

School students survey in

Camenga et al
Zhu et al

<21

0.14

NY and CT, Knowledge

21-35

0.072

Networks Panel Survey

36-50

0.059

51-65

0.082
0.002

>65
Gender

Discrete

Male

0.049

Female

0.086

Race
0.075

Black

0.062

Other

0.014

Education status

Knowledge

School students survey in

Camenga et al
Zhu et al

less than high school

0.088

NY and CT, Knowledge

more than high school

0.066

Networks Panel Survey

any college

0.045
Discrete

International Tobacco

Low

0.016

Control Four Country

Medium

0.014

Survey (ITC-4) data

High

0.021

Quit attempts within past
12 months

Zhu et al

Networks Panel Survey

Discrete

FTND Score

Zhu et al

Networks Panel Survey
Discrete

White

Knowledge

Discrete

Legacy Longitudinal

None

0.013

Smoker Cohort (LLSC)

At least 1

0.037

survey data

Kasza et al

Pearson et al

Table 6. E-cig initiating probabilities and assigned distribution for current smokers.

Table 6 presents the mutually unexclusive probabilities associated with the initiation of
e-cig based on different attributes, in current smokers. The highest probability of

initiation was found to be in the age group of <21 years (0.35) compared to other age
groups. Females (0.56), whites (0.48), and those who had less than high school
education (0.49) had a higher probability than their counterparts. With respect to
smoking-related attributes, smokers having a high nicotine dependence (0.52) and
those who had at least one quit attempts in the past (0.64) had a higher probability than
their counterparts.

Parameters

E-cig use
probability

Age, years

Assigned probability
distribution

Data

Source

Continuous

School students survey in

Camenga et al
Zhu et al

<21

0.100

NY and CT, Knowledge

21-35

0.073

Networks Panel Survey

36-50

0.059

51-65

0.082

>65

0.026

Gender

Discrete

Male

0.049

Female

0.076

Race
0.076

Black

0.062

Other

0.028

Education status

Zhu et al

Networks Panel Survey
Discrete

White

Knowledge

Knowledge

Zhu et al

Networks Panel Survey

Discrete

School students survey in

Camenga et al
Zhu et al

less than high school

0.088

NY and CT, Knowledge

more than high school

0.066

Networks Panel Survey

any college

0.045

Table 7. Baseline attributes, corresponding probabilities and assigned distribution for recent former smokers.

Table 7 presents the probabilities associated with the initiation of e-cig in recent former
smokers. Similar to current smokers, the highest probability of initiation was found to
be in the age group of <21 years (0.31), females (0.51), whites (0.44), and those who
had less than high school education (0.51).

Parameters

E-cig use
probability

Age, years

Assigned probability
distribution

Data

Source

Continuous

School students survey in

Camenga et al
Zhu et al

<21

0.039

NY and CT, Knowledge

21-35

0.011

Networks Panel Survey

36-50

0.004

51-65

0.032

>65

0.001

Gender

Discrete

Male

0.002

Female

0.008

Race
0.008

Black

0.001

Other

0.003

Education status

Zhu et al

Networks Panel Survey
Discrete

White

Knowledge

Knowledge

Zhu et al

Networks Panel Survey

Discrete

School students survey in

Camenga et al
Zhu et al

less than high school

0.002

NY and CT, Knowledge

more than high school

0.001

Networks Panel Survey

any college

0.007

Table 8. Baseline attributes, corresponding probabilities and assigned distribution for late former smokers.

Table 8 presents the probabilities associated with the initiation of e-cig in late former
smokers. The highest probability of initiation was found to be in the age group of 21-35
years (0.36), females (0.51), whites (0.41), and those who had college level education
(0.43).

Parameters

E-cig use
probability

Age, years

Assigned probability
distribution

Data

Source

Continuous

School students survey in

Camenga et al
Zhu et al

<21

0.011

NY and CT, Knowledge

21-35

0.007

Networks Panel Survey

Gender

Discrete

Male

0.005

Female

0.007

Race

Networks Panel Survey
Discrete

White

0.006

Black

0.006

Other

0.001

Education status

Zhu et al

Knowledge

Zhu et al

Knowledge
Networks Panel Survey

Discrete

School students survey in

Camenga et al
Zhu et al

less than high school

0.008

NY and CT, Knowledge

more than high school

0.006

Networks Panel Survey

any college

0.004

Table 9. Baseline attributes, corresponding probabilities and assigned distribution for never smokers.

Table 9 presents the probabilities associated with the initiation of e-cig in never
smokers. Since we assumed that never smokers will not initiate e-cig use after 35 years,
we only used probabilities of <21 years and 21-35 years age groups. The age group <21
years (0.58), females (0.53), whites (0.47), and those who had college level education
(0.45) had a higher probabilities than their counterparts.

Creating smokers and assigning
baseline characteristics based
on the NHIS population data

Recording e-cig prevalence, aging
of the population, going back into
the loop and population exodus
Assigning use of e-cig based on
population attributes and
incorporating different e-cig use
scenarios

Figure 4. E-cig use simulation model

E-cig Prevalence in Current Cigarette Smokers
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Figure 5. Projected estimate of e-cig prevalence among initial current cigarette smokers

Figure 5 presents the projected e-cig use for the overall population of current cigarette
smokers in the US. The prevalence was found to increase steadily from around 2% in the
first year to around 6.7% in the eight years. From there onwards, the increase was found to
slow down and found to be 7.9% at the end of the simulation period.
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Figure 6. Projected e-cig prevalence by age group among initial current cigarette smokers in the US.

Figure 6 presents the projected estimates of e-cig use by age group among current cigarette
smokers. The highest prevalence at the end of the simulation period was found in smokers
in the age group of 6-20 years. It was followed closely by smokers in the age group of 21-35
years. The highest number of e-cig users after those two categories were found to be in 5165 years, 36-50 years and lowest in over 65 years.
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Figure 7. Projected e-cig prevalence by gender among initial current cigarette smokers in the US.

Figure 7 presents the projected estimates of e-cig use by gender among current cigarette
smokers. Males and females showed approximately the same prevalence through the
simulation period. Males were found to be slightly higher users at the end of the simulation
period.
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Figure 8. Projected e-cig prevalence by race among initial current cigarette smokers in the US.

Figure 8 presents the projected estimates of e-cig use by race among current cigarette
smokers. Smokers belonging to the white race consistently showed a higher e-cig use than
smokers belonging to the black and other races. Current smokers belonging to races other
than black and white showed the lowest prevalence.
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Figure 9. Projected e-cig prevalence by education among initial current cigarette smokers in the US.

Figure 9 presents the projected estimates of e-cig use by education level race among
current cigarette smokers. The highest e-cig use was projected in the smokers who had less
than high school level education compared to smokers with either a high school education
or a college degree. The prevalence was not very different between the current smokers
having a high school degree or a college level education.

E-cig Prevalence in Recent Former Cigarette Smokers
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Figure 10. Projected estimate of e-cig prevalence among initial recent former cigarette smokers

Figure 10 presents the projected e-cig use for the overall population of recent former
cigarette smokers in the US. Here, the prevalence of e-cig use was found to increase steadily
from around 2% in the first year to around 7.5% at the end of the simulation period. The
increased in prevalence was observed to slow down near the end of the simulation period,
around the 8th year.
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Figure 11. Projected e-cig prevalence by age group among initial recent former cigarette smokers in the US.

Figure 11 presents the projected estimates of e-cig use in recent former smokers classified
by different age groups. The highest prevalence at the end of the simulation period was
found in smokers in the age group of 6-20 years. It was followed by smokers in the age
group of 21-35 years. The prevalence in the age group 36-50 years, and 51-65 years were
found to be nearly equal at the end of the simulation period. The e-cig use was found to be
lowest in the age group of >65 years.
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Figure 12. Projected e-cig prevalence by gender among initial recent former cigarette smokers in the US.

Figure 12 presents the projected estimates of e-cig use by gender among recent former
cigarette smokers. Unlike the current smokers, the prevalence of e-cig use was projected to
be higher in females than males. The gap between males and females however reduced as
the simulation progressed.
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Figure 13. Projected e-cig prevalence by race among initial recent former cigarette smokers in the US.

Figure 13 presents the projected estimates of e-cig use by race among recent former
cigarette smokers. Similar to the projection in current smokers, recent former smokers
belonging to the white race consistently showed a higher e-cig use than smokers belonging
to the black and other races. Recent former smokers belonging to the black race showed
the lowest prevalence.
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Figure 14. Projected e-cig prevalence by education among initial recent former cigarette smokers in the US.

Figure 14 presents the projected estimates of e-cig use by different education level among
recent former cigarette smokers. The highest e-cig use was projected in the smokers who
had a less than high school education, followed closely by smokers who had a college
degree, and finally in smokers who had at least a high school education.

E-cig Prevalence in Late Former Cigarette Smokers
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Figure 15. Projected estimate of e-cig prevalence among late former cigarette smokers in the US.

Figure 15 presents the projected e-cig use for the overall population of late former
cigarette smokers in the US. Unlike the e-cig prevalence in late former smokers, the
prevalence of e-cig use in late former smokers was projected to be lower in magnitude. The
prevalence grew steadily from approximately 0.3% to 1% in first four years, and then
showed very little increase for the rest of the simulated period. The prevalence was found
to be 2.9% at the end of the simulation period.
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Figure 16. Projected e-cig prevalence by age group among initial late former cigarette smokers in the US.

Figure 16 presents the projected estimates of e-cig use in recent former smokers classified
by different age groups. Among different age groups, the highest prevalence at the end of
the simulation period was found in smokers in the age groups of 21-35 years. Following
that, the age groups 36-50 years and 51-65 years showed the next highest number of e-cig
users. The lowest number of e-cig users were found to be in the age groups of 6-20 years
and >65 years.
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Figure 17. Projected e-cig prevalence by gender among initial late former cigarette smokers in the US.

Figure 17 presents the projected estimates of e-cig use by gender among late former
cigarette smokers. The projected estimates showed that the prevalence was similar in
males and females through the simulation period. Initially, females had a higher number of
e-cig users but at the of the simulation period, males showed higher use than females.
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Figure 18. Projected e-cig prevalence by race among initial late former cigarette smokers in the US.

Figure 18 presents the projected estimates of e-cig use by race among late former cigarette
smokers. The majority of e-cig users among late former smokers belonged to the white
race. Both black and other races projections showed a similar number of e-cig users at the
end of the simulation period.
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Figure 19. Projected e-cig prevalence by education among initial late former cigarette smokers in the US.

Figure 19 presents the projected estimates of e-cig use by different education levels among
late former cigarette smokers. Among late former smokers, the highest e-cig use was
projected in the smokers who had at least a college level education. Less than high school
education and high school education had lower number of e-cig users.

E-cig Prevalence in Never Cigarette Smokers
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Figure 20. Projected estimate of e-cig prevalence among initial never cigarette smokers in the US.

Figure 20 presents the projected e-cig use for the overall population of never cigarette
smokers in the US. Similar to the late former smokers, the e-cig prevalence in never
smokers was projected to be lower in magnitude. The prevalence grew steeply from 0.12%
to 1.1% in first five years, and then showed an increase to 1.8% at the end of the simulation
period.
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Figure 21. Projected e-cig prevalence by age groups among never cigarette smokers

Figure 21 presents the projected estimates of e-cig use in never smokers classified by the
two age groups. The prevalence at the end of the simulation period was found higher
among never smokers in the age groups of 6-20 years than those in 21-35 years. Both age
groups showed a steep rise in e-cig use for first 5 years and then showed a steady raise till
the end of the simulation period.

1.2

Percentage prevalence

1
0.8
0.6
0.4
0.2
0
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

Years
Male

Female

Figure 22. Projected e-cig prevalence by gender among never cigarette smokers

Figure 22 presents the projected estimates of e-cig use by gender among never cigarette
smokers. The projected estimates showed that the prevalence was almost similar in males
and females at the beginning of the simulation period, and at the end of the simulation
period females were found to be higher users of e-cigs.
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Figure 23. Projected e-cig prevalence by race among never cigarette smokers

Figure 23 presents the projected estimates of e-cig use by race among never cigarette
smokers. Similar to other smoking categories, the majority of e-cig users among never
smokers belonged to the white race. The projected estimates showed a consistent white
majority of never smokers who became e-cig users, compared to black and other races
through the simulation period. Never smokers belonging to other races showed a slightly
higher number of e-cig users projections compared to black smokers.

0.9

Percentage prevalence

0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

Years
Less than high school

High school

College

Figure 24. Projected e-cig prevalence by education level among never cigarette smokers

Figure 24 presents the projected estimates of e-cig use by different education levels among
never cigarette smokers. The highest number of e-cig users was projected in never smokers
who had less than high school level education. It was followed by never smokers who had
at least high school education. Lastly, the lowest number of e-cig users among never
smokers had a college degree.
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Figure 25. Projected estimate e-cig prevalence in the US population over the simulation period.

Figure 25 presents the projected e-cig use in the model population over the simulation
period. It was observed that the e-cig use showed a steady growth till the 7th year (15.8%),
and then showed a decline in the growth from 7th until the 15th year. The e-cig prevalence
at the end of the simulation period was found to be 19.3%.
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Figure 26. Comparison of projected e-cig use and conventional cigarette use over the simulation period.

Assuming all the conventional cigarette users transitioned completely to e-cig use without
any dual use period, we compared the projected e-cig use and the conventional cigarette
use over the same simulation period (Figure 26). In the conventional cigarette use group,
the initial population consisted of smokers in the CS, RFS and LFS groups. Each subsequent
year, the total number of e-cig users at the end of each year from these three groups were
subtracted from the conventional cigarette group, since we assumed that once a person
switched to e-cig use, he or she could not go back to using conventional cigarette. The
conventional cigarette use was found to reduce from 40% to 25% at the end of simulation
period.
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Figure 27. Projected e-cig prevalence by age groups in the US population

Figure 27 presents the projected estimates of e-cig use classified by different age groups.
Among different age groups, the highest prevalence at the end of the simulation period was
found in people who belonged to the age groups of <21 years and 21-35 years old. It was
followed by age group 51-65 years and 36-50 years and the lowest number of e-cig users
were found to be in the age groups of >65 years.
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Figure 28. Projected e-cig prevalence by gender in the US population

Figure 28 presents the projected estimates of e-cig use by gender. It was observed that in
the initial stages, e-cig use was more prevalent in females compared to females. However,
at the end of the simulation period the prevalence was almost similar in males and females,
approximately 9.5%.
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Figure 29. Projected e-cig prevalence by race in the US population

Figure 29 presents the projected estimates of e-cig use by race. It was observed that the
majority of e-cig users belonged to the white race. The projected estimates showed a
consistent white majority of e-cig users through the simulation period, compared to black
and other races. Further, people who belonged to the black race showed a higher e-cig use
than other racial groups.
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Figure 30. Projected e-cig prevalence by education level in the US population

Figure 30 presents the projected estimates of e-cig use by different education levels. The
highest number of e-cig users belonged to people with less than high school education. It
was followed by people who had at least a college degree, and then people who had at least
high school level education.

Sensitivity Analyses

Scenarios
Reduction in initiating
risk due to policy
2%
3%
5%

Prevalence in current smokers (end of
15 years)
18.32%
16.19%
14.78%

Change in timing of
policy implementation
5 years
10 years
No Policy

18.68%
21.93%
23.47%

Proportion of people making a quit
attempt within a year (±15%)
33%
63%

18.14%
20.28%

Proportion of people staying quitter
for that year (±15%)
14%
4%

18.91%
19.95%

Table 10.Prevalence estimates at the end of 15 years for different scenarios in sensitivity analyses in current smokers

Prevalence of e-cig use was found to be most sensitive to change in risk associated with
policies, and time of implementation of the policies. When the risk was increased to 2%
each year, the prevalence at the end of the simulation period was found to be reduced to
18.32% from 19.33%. Increasing it further to 3% and 5% resulted in the reduction of
prevalence to 16.19% and 14.78%, respectively. Similarly when the time of policy
application was changed from 7 years to 5 years, prevalence reduced from 19.33% to
18.68%. When it was changed to 10 years, the prevalence increased to 21.93%. When there
was no policy application at all, the prevalence was increased to 23.47%. We also evaluated

the impact of changing the proportion of people making a quit attempt, and making a
relapse within the same year. The results of this scenarios did not show a huge impact on
the prevalence of e-cig use the end of the simulation period. On decreasing and increasing
the proportion of people making a quit attempt within a year by 15% resulted in a final
prevalence of 18.14% and 20.28%, respectively. On decreasing and increasing the
proportion of people staying a quitter for that year after making a quit attempt by 15%,
resulted in a final prevalence of 18.91% and 19.95%, respectively.

Chapter 4

Discussion

The primary objective of this study was to develop a validated DES model to allow for the
assessment of e-cig use behavior and prevalence of e-cig in different population groups,
using data from literature review of several cross-sectional survey and longitudinal e-cig
studies done on the US population. The simulation replicated the initiating patterns, quit
attempts and relapses associated with the e-cig use in current, former and never cigarette
smokers. The model also allowed the change of smoking status between the three smoking
groups, through the simulation period. We were also able to apply the effect of history by
including information on prior simulated quit attempts, in addition to individuals’
characteristics at the time of each subsequent quit attempt, to make predictions. Further,
the model gave us an opportunity to investigate the impact of e-cig related policies on the
prevalence patterns into the future and examining possible real-life patterns of e-cig use.

Our study results showed that e-cig use was projected to be the highest in current cigarette
smoking population, followed by recent former smokers, late former smokers and lowest in
never smokers. The projected estimate after the first year of simulation in current smokers
was found to be around 2.1%. This finding was found to be consistent with the results of a
survey conducted by CDC which reported the prevalence of regular e-cig use to be around
1.9% (King et al., 2013). It provides initial evidence to support the model validity and its
potential to obtain accurate estimates with adequate data availability. The overall
projected e-cig use for the population of current cigarette smokers in the US was found to
increase to 6.7% in eight years, and then to 7.9% at the end of the simulation period. The
slow growth rate after 8 years could be attributed to the launch of the e-cig control policy,

which was implemented at the 7th year, and which resulted in lowering risk of initiation of
e-cig each subsequent year. Next, the prevalence of e-cig use in recent former smokers was
found to be less than current smokers, but still considerably higher than late former and
never smokers. The e-cig use pattern followed the same trajectory as in current smokers,
indicating the behavior of recent former and current smokers towards the use of e-cig is
not very different. In late former smokers and never smokers, the e-cig use was projected
to be lower than current and recent former smokers. This was consistent in current trend
in the use of e-cig, where the only never smokers who become regular e-cig users are
relatively young adults and teenagers, resulting in a low overall population prevalence
(Camenga et al., 2014).

Differences in the use of e-cigarettes were observed across subpopulations. Specifically,
younger age groups, whites, females and smokers having less than high school education
were found to be highest users of the e-cig among current, recent former, and never
smokers. Higher use among younger adults may be related to the fact that e-cigarettes are
traditionally marketed through electronic and social media (Noel, Rees, & Connolly, 2011;
Yamin, Bitton, & Bates, 2010). Also, the higher prevalence of use among current smokers
could be related to the marketing of e-cigarettes as smoking cessation aids (Adkison et al.,
2013; Etter & Bullen, 2014).

Our research provides context to identify future population-based changes related to e-cig
use and guide the design of a more informative longitudinal research. National data on ecig use by middle and high school students gathered via the National Youth Tobacco Survey

in 2011 and 2012 reported that among middle and high school students, ever-use of ecigarettes (tried at least once) increased from 3.3% to 6.8%, whereas current use (within
the last 30 days) increased from 1.1% to 2.1% (Agaku et al., 2014). That data was correctly
estimated by our model as observed by the results of the 1st year simulation. Another
analysis of National Youth Tobacco Survey data from the same time period confirmed that
current e-cigarette users were much more likely to be current cigarette smokers, which
was consistent with our findings (Bunnell et al., 2015).

Our study is also a first in modeling the impact of future policies regulating e-cigs at
different times. Because e-cig is a new product, lack of scientific evidence has been a key
factor for the absence of federal regulations. Our study provides an opportunity to examine
the potential impact of future policies on e-cigs use by modeling risk reduction each
subsequent year after implementation of a policy. Another advantage of our study was that
we were able to show the impact of varying the policy effect, specifically the magnitude of
risk and the time at which the policy will be implemented, in our sensitivity analyses.

Our model also enables meaningful analyses of outcomes in population subgroups. For
instance, the prevalence of e-cig use among younger age group and white people could be
more comprehensively captured. By accounting for subject characteristics when predicting
e-cig use, relapse, and quit attempts, this model provides a powerful tool to evaluate the
usefulness of e-cigs for improving quit rates, and reducing the risk of relapse among
different subgroups of the population.

With the current ongoing research on the health effects related to the use e-cigs, this model
could be used to predict vaping-related disease and health utilities once the data becomes
available. Although the exact information on diseases attributed to e-cig use is not be
expected to come out in near future, but the effects on proxy measures, such as
physiological biomarkers, will be able to provide some insight in the risks related to the use
of e-cigs.

We have to be mindful of the fact that a large proportion of current e-cig users are
concurrently using conventional cigarettes (Brandon et al., 2015). Since we did not have
access to longitudinal individual level data, we were not able to model the time dependent
aspects of e-cig behavior such as time to first quit attempt, time to relapse, time spent by a
smoker in transitioning from cigarette to e-cig. This information when available, could be
used by the investigators to predict the time-dependent aspects listed above to estimate
important outcomes such as duration of time where the current cigarette smoker is using
both product (dual use), or time taken to completely switch to e-cig.

The main strength of this model is that it was able to incorporate significant predictors of
e-cig initiation obtained from the literature and show their cumulative effect in making the
individuals use or not use an e-cig. Thus, this model structure could provide a solid
foundation from which a flexible, lifetime e-cig use behavior model can be developed that
can accommodate multiple quit attempts, relapse, transitioning between current, former
and never users over time in diverse populations.

The main impediment to developing a lifetime DES is the difficulty in obtaining accurate
and reliable data on long term patterns of quit attempts. Data that would allow for accurate
individualized predictions on sequences of smoking behavior, intervals between quit
attempts and long-term relapse rates, are required to fully harness the potential of the
modelling technique. Nevertheless, even in the absence of these data, a lifetime DES built
on the current model would allow for informative exploratory analyses that are grounded
in reliable individualized predictions and patterns. Based on our literature review, we
believe that the data is currently being collected and will be released sometime in near
future. Once the data is available, capturing the time-dependent relationships will add
tremendous value to a lifetime model.

We believe that the data related to e-cig attributed mortality will not become available in
near future. Hence, it will not be possible to model the mortality rates related to e-cig use.
However, it is certainly possible to use the rates of smoking-related disease attributed to ecig use, compare them with disease rates attributed to conventional cigarette smoking and
other tobacco products, and predict mortality after applying appropriate assumptions.

In future, additional validation of the model predictions would also increase confidence in
the reliability of the current predictive equations. The structural validation and the
comparison of the results against the data sources indicated that the simulation predicted
the short term prevalence estimates close to the real values, and performed well when

implemented in key population subgroups. However, validation exercises performed
against sources different than those used in developing the core equations would be
valuable.

Data on e-cig use by youth and adults have been gathered primarily from Web-based
surveys and convenience sampling, including regional samples, and from participants in
online e-cigarette forums. Interpreting such data is difficult, and it is necessary that data
collected at the individual level is released publicly, to foster research on different areas of
interests related to e-cigs. Furthermore, most of the cross sectional or survey research
published till date use has evaluated just the short term use of e-cig use, mostly for 1 or 2
years. Similarly, the clinical trials studies conducted on e-cig use have also followed the ecig users for the duration of 6 months or 12 months. Our model used that information,
incorporated into our model, followed the e-cig users for 15 years, and tried to project the
behavior pattern and the use trajectory of e-cigs.

Some studies observed that e-cigs may contribute to prevent relapse in former smokers
and to promote smoking cessation in current smokers, which essentially means getting
them off from conventional cigarettes (Biener & Hargraves, 2015; McMillen et al., 2014). It
would have been a significant outcome to look at in our model as well however, the
evidence is still scarce according to our review of the published literature.

We made a strong assumption in our study that all e-cigs contained nicotine. The recent
policy statement on e-cigs from the American Association for Cancer Research reported
that currently there are around 7000 unique flavored e-cigs on the market (Brandon et al.,
2015). The report suggested that flavored tobacco is particularly appealing to youth, and
some flavored combustible products potentiate continued use and addiction. There is a
concern that flavored e-cigs may have a similar effect on the youth, however there is no
available studies which have accessed flavors in general (Brandon et al., 2015). In future,
our model can be used when the data on flavors becomes available, to estimate the impact
of different flavors on the pattern of e-cig use among the young users.

The use of e-cigs by never smokers would present a public health concern, but this is a
particular concern with respect to youth, especially if e-cigs serve as a pathway to other
tobacco products, including combustible cigarettes (Grana, 2013). In our study, we were
limited by the data availability and could only estimate the transition of never smokers to
e-cigs but could not model their transition to the use of regular tobacco products. However
in near future, with the availability of adequate data, we could show transition of never
smokers from e-cigs to other tobacco products can be a significant application of this
model.

Population benefit or harm depends largely on public’s perception of the products and
their patterns of use. The risk may increase if dual use with other tobacco products is
prevalent, or cessation is deterred by persons using e-cigs to circumvent smoke-free laws.

Studies conducted with e-cigarette users, demonstrated that they perceive the products to
be less toxic than conventional cigarettes and have used them as a smoking cessation
device or to avoid exposing others to tobacco smoke (Brown et al., 2014; Pearson et al.,
2012). However, the research on their efficacy for smoking cessation is still ongoing and
most of the published studies reported a small sample size making their studies
underpowered. Further research on the rates and health effects of dual use is critical for
assessing and considering total public health impact of e-cigs. Future studies should try to
assess the dose–response relationship for certain biomarkers of cardiovascular effects or
lung cancer effects with the use of e-cigs.

The evidence regarding the risks and benefits of e-cigs in different segments of the
population such as current smokers and never smokers is difficult to interpret, because the
market place of e-cigs products is evolving rapidly. Research in this field is complicated by
the ever-changing and wide variability among and within different e-cig products, a lack of
standardized definitions of e-cigs, variable user terminology, and a lack of established
protocols for conducting e-cig research, including clinical trials (Brandon et al., 2015).
However, despite these challenges, research on e-cigs is on the right track and progressing
rapidly. The NIH and the FDA are providing recommendations for studying these products,
including different population sub groups such as healthy volunteers as well as vulnerable
populations, such as people suffering from cancer and those with other acute or chronic
medical conditions. More research is needed to understand how different design features
relate to dependence and toxicity, including if the compounds in e-cigs react chemically and
if these compounds are absorbed into the bloodstream. Research is also needed to

understand the effect e-cig use, including second- and third hand exposure to population as
well. Studies should also examine the efficacy and safety of e-cigs in patients with cancer
treated with surgery, chemotherapy, and radiotherapy and potential interactions with
these therapies. Among smokers, long term controlled clinical trials are needed to
determine whether e-cigs facilitate or hinder short- and long-term smoking cessation as
well as whether it increases nicotine dependence. Studies should consider also outcomes
related to health conditions such as cardiovascular diseases, COPD, lung cancer and stroke.
These conditions have an established history with conventional cigarette smoking.

Limitations

The biggest limitation of this study was the use of self-reported values of e-cig use based on
age, gender, race and education status. Due to the absence of standardized recorded
individual level data, we were unable to obtain the mutually exclusive prediction
probabilities. However, we used appropriate mathematical rules to get a correct estimate
of the probabilities associated with the e-cig use. The model also relied on a number of data
sources, including surveys and longitudinal e-cig studies done on the different populations,
which may be responsible for variation in the results across different groups. Another
limitation was not able to differentiate people who make a quit attempt and relapse, and
those who do not relapse. We did allow a definite proportion of people to pass through, but
that proportion was directly utilized from a survey without the knowledge of individual
characteristics of people making or not making the quit attempt or relapse (Kasza et al.,
2014). Next important limitation was that we could not validate our model projections
against real world data. Because e-cig is a relatively new product, long term longitudinal
studies will be required to compare and validate the results of our model. Additionally,
time to quit attempt, time to relapse, and time to transition from regular cigarette to e-cig
was not modelled because of lack of time dependent data. Because the smokers were
generated and assigned attributes based on the NHIS data, simulated patients may not
accurately represent real-world patients, which could limit generalizability to real-world
settings. In addition, we assumed everyone to be undergoing the changes and going
through different states as defined by the path of the model. This does not happen in the
real world, where the movement of people is more dynamic and random.

Chapter 5

Conclusion

The benefits and harms of e-cig use must be evaluated with respect to the population as a
whole and take into account the effect on youth, adults, never smokers, former smokers
and current smokers. There are currently too few data on the behavior pattern of e-cigs
and their efficacy as cessation products to recommend their use for the general population.
Our study evaluates the long term use pattern of e-cigs in the US population. We mainly
estimated the prevalence of e-cigs in current, former and never smokers for the period of
15 years, using the current data. Our population model will help predict changes in
individual behaviors and patterns associated with the use of e-cigs. It will also help to
address the problem of scarce data resources related to e-cig use and provide guidance for
conducting more research on generating real world evidence to look into more relevant
outcomes. It will also encourage policymakers to review the rapidly changing pattern of ecig use and make public health decisions by using our future projection of e-cig use.
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Appendix

Table 11. Model Population descriptive results:
Current smokers
(N= 12665)

Former smokers
(N= 15226)

Never smokers
(N=40801)

Age (%)
<21 years

1.825

0.511

2.771

21-35 years

34.701

13.602

29.484

36-50 years

33.901

18.954

30.732

51-65 years

23.760

31.671

22.859

>65 years

5.811

35.272

14.151

Male

55.554

52.453

42.115

Female

44.445

47.556

57.884

White

68.279

80.394

66.37

Black

13.949

8.061

12.228

Other

17.771

11.552

24.534

Less than high school

9.615

11.598

63.237

High school diploma

43.781

37.813

12.228

46.603

50.589

24.534

CPD (Means, SD)

11.87, 8.80

-------------

--------------

Years of regular smoking
(Means, SD)

27.02, 15.69

Gender

Race

Education status

Any college

At least 1 quit attempt in
past 12 months

46.97

---------------

--------------

Simulated population for 5 years
Years
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Initial N=
100000.00
100000.00
100478.83
100959.95
101443.37
101929.11
102417.18
102907.58
103400.33
103895.44
104392.92
104892.78
105395.04
105899.70
106406.78

+ Birth rate

-Death rate

Total
population

0.00
101330.00
101815.20
102302.72
102792.57
103284.77
103779.33
104276.25
104775.55
105277.25
105781.35
106287.86
106796.79
107308.17
107821.99

0.00
100478.83
100959.95
101443.37
101929.11
102417.18
102907.58
103400.33
103895.44
104392.92
104892.78
105395.04
105899.70
106406.78
106916.28

100000.00
100478.83
100959.95
101443.37
101929.11
102417.18
102907.58
103400.33
103895.44
104392.92
104892.78
105395.04
105899.70
106406.78
106916.28

Table 12. Simulated population for each year after applying the birth and death rates

Prevalence estimates for each year
Years
Overall
Percent
Prevalence
Standard
errors

1

2.0952
0.852

2

3.1025
0.767

3

3.9464
0.813

4

4.5391
0.675

5

5.1388
0.684

6

5.8339
0.774

7

6.1518
0.868

8

6.6226
0.796

9

6.9427
0.873

10

7.2835
0.782

11

7.3419
0.654

12

7.5792
0.861

13

7.6215
0.882

14

15

7.6802

7.7148

0.768

0.685

Age
6-20 years

0.5826

0.9695

1.2824

1.4517

1.6182

1.8133

2.0445

2.0865

2.1158

2.2344

2.2705

2.2953

2.3284

2.3164

2.3941

21-35 years

0.5381

0.7115

0.9218

1.2703

1.4681

1.5212

1.6367

1.7366

1.9511

2.0468

2.1718

2.2674

2.2931

2.3075

2.3413

36-50 years

0.1794

0.2285

0.4001

0.6269

0.8405

0.9502

1.0414

1.0508

1.0843

1.0229

1.0643

1.0834

1.1648

1.1592

1.1692

51-65 years

0.5939

0.6424

0.9912

1.2189

1.3881

1.4943

1.5048

1.6676

1.6991

1.8369

1.7642

1.7149

1.7298

1.7643

1.7985

>65 years

0.2012

0.2112

0.2088

0.1888

0.1315

0.1244

0.1561

0.1625

0.1225

0.0625

0.0682

0.0546

0.0513

0.0496

0.0482

Male

0.9312

1.4244

1.8615

2.1164

2.5347

2.8361

2.9832

3.3398

3.6464

3.7331

3.7251

3.8563

3.8426

3.9321

3.9167

Female

1.1643

1.6687

2.0437

2.3802

2.6918

2.9239

3.1748

3.2937

3.4235

3.5525

3.6278

3.7231

3.7825

3.7514

3.8024

White

1.0985

1.4027

1.8233

2.1594

2.3637

2.5579

2.7679

2.9042

3.0492

3.1856

3.2041

3.2984

3.3231

3.3649

3.4025

Black

0.8543

1.1145

1.4529

1.7638

1.9286

2.1242

2.2404

2.4497

2.5234

2.6493

2.6643

2.7673

2.7965

2.8052

2.8543

Other

0.3424

0.5619

0.6588

0.8034

0.8408

1.1254

1.1335

1.3289

1.3856

1.4675

1.5124

1.5243

1.5671

1.5241

1.5934

0.8367

1.4694

1.7032

1.9367

2.2411

2.4358

2.5636

2.7027

2.8613

2.9152

3.0734

3.1243

3.1906

3.2834

3.3127

Gender

Race

Education
level
Less than high
school

High school
College

0.5985

0.8163

1.0102

1.1423

1.3365

1.5272

1.6598

1.7668

1.8379

1.9316

1.8854

1.9465

1.8437

1.8671

1.8207

0.66

1.0174

1.2418

1.4666

1.5612

1.8809

1.9484

2.1643

2.2134

2.3123

2.3965

2.5119

2.5974

2.6074

2.6846

Table 13. Projected e-cig prevalence for each year in the simulation period within different demographic categories of current cigarette smokers.

Prevalence estimates for each year
Years
Overall
Percent
Prevalence
Standard
errors

1

2.0444
0.852

2

3.5079
0.767

3

4.4298
0.813

4

5.2325
0.675

5

5.7254
0.684

6

6.1126
0.774

7

6.6843
0.868

8

7.1021
0.796

9

7.2324
0.873

10

7.3062
0.782

11

7.3483
0.654

12

7.3841
0.861

13

7.4267
0.882

14

15

7.4608

7.5117

0.768

0.685

Age
6-20 years

0.8584

1.4431

1.8023

2.1168

2.2941

2.4029

2.4967

2.5069

2.5993

2.6026

2.6037

2.6041

2.6571

2.6519

2.6934

21-35 years

0.5852

0.9058

1.1331

1.3213

1.4415

1.6039

1.8146

2.0217

2.1132

2.2102

2.2167

2.2583

2.3119

2.3508

2.3781

36-50 years

0.3803

0.6961

0.9849

1.0673

1.1589

1.2704

1.3198

1.4625

1.4492

1.4951

1.4803

1.4545

1.4237

1.4209

1.4068

51-65 years

0.117

0.3275

0.4829

0.6125

0.8047

0.9754

1.0975

1.1189

1.1136

1.0239

1.0228

1.0193

1.0346

1.0285

1.0274

0.06963

0.0718

0.0926

0.1006

0.09872

0.09312

0.0857

0.0755

0.0729

0.0615

0.0601

0.0583

0.0549

0.0486

0.0431

Male

0.8199

1.5683

2.0191

2.3315

2.4435

2.8098

3.1144

3.4887

3.4852

3.5228

3.5579

3.5816

3.5894

3.5926

3.6051

Female

1.2267

1.9456

2.4148

2.9014

3.2851

3.3178

3.5714

3.6124

3.7479

3.7845

3.7901

3.8002

3.8373

3.8719

3.9047

White

1.0949

1.7359

2.1449

2.7073

2.9332

3.2344

3.4121

3.5218

3.6012

3.6424

3.6593

3.6804

3.6979

3.7014

3.7107

Black

0.4163

0.9577

1.0825

1.1132

1.2802

1.3151

1.4754

1.6535

1.5981

1.5972

1.6043

1.5941

1.5538

1.5406

1.5912

Other

0.5356

0.8247

1.2085

1.4122

1.5161

1.7275

1.8078

1.9358

2.0314

2.1574

2.1701

2.2045

2.2179

2.2282

2.2196

Less than high
school

0.6832

1.2108

1.6356

1.9082

2.1088

2.2772

2.4736

2.6997

2.7104

2.7829

2.7902

2.8007

2.8517

2.8861

2.8942

High school

0.4737

0.8826

1.0617

1.2959

1.4042

1.5114

1.7323

1.8052

1.9421

1.9602

1.9054

1.9342

1.9865

1.9907

1.9145

>65 years

Gender

Race

Education
level

College

0.8748

1.4085

1.7325

2.0284

2.2124

2.3244

2.4676

2.5215

2.584

2.6163

2.6304

2.6584

2.6841

2.689

Table 14. Projected e-cig prevalence for each year in the simulation period within different demographic categories of recent former cigarette smokers.

2.7123

Prevalence estimates for each year
Years
Overall
Percent
Prevalence
Standard
errors

1

0.2968
0.152

2

3

0.6148

0.8914

0.167

0.183

4

1.1746
0.175

5

6

7

8

9

1.3793

1.5313

1.6759

1.7946

1.9372

0.184

0.174

0.168

0.196

0.173

10

2.0112
0.182

11

12

13

14

15

2.1409

2.1764

2.2034

2.2374

2.2946

0.154

0.181

0.182

0.168

0.185

Age
6-20 years

0.1433

0.1763

0.1856

0.1942

0.2243

0.2772

0.2868

0.3126

0.3243

0.3346

0.3371

0.3458

0.3549

0.3824

0.3945

21-35 years

0.1239

0.2061

0.2409

0.2967

0.3909

0.4874

0.5224

0.5903

0.6493

0.7824

0.8106

0.8347

0.8643

0.8943

0.8973

36-50 years

0.05784

0.1084

0.1423

0.1698

0.2691

0.3029

0.3407

0.3941

0.4172

0.438

0.4672

0.4827

0.5042

0.5247

0.5382

51-65 years

0.0685

0.1258

0.1931

0.2413

0.2915

0.3342

0.3616

0.4022

0.4391

0.4482

0.4691

0.4782

0.4893

0.5092

0.5247

0.00317

0.0179

0.0318

0.0259

0.0357

0.0414

0.04176

0.04123

0.0409

0.04124

0.0462

0.0497

0.0582

0.0416

0.0472

Male

0.1415

0.2853

0.4312

0.5291

0.6407

0.7734

0.8125

0.9042

0.9313

1.0942

1.258

1.211

1.218

1.241

1.2954

Female

0.1541

0.2951

0.4673

0.6413

0.6683

0.7667

0.8534

0.8946

0.9067

0.9184

0.9361

0.9643

0.9833

0.9892

1.0028

White

0.1953

0.2774

0.3986

0.4928

0.6147

0.6913

0.7105

0.7831

0.8182

0.9395

1.0523

1.0612

1.1085

1.1191

1.1574

Black

0.0215

0.1442

0.2326

0.3201

0.3731

0.3966

0.4091

0.4127

0.4813

0.4977

0.5413

0.5543

0.5691

0.5724

0.5746

Other

0.0795

0.2085

0.2774

0.3695

0.4313

0.4839

0.5084

0.5225

0.5876

0.6187

0.6431

0.6582

0.6307

0.6479

0.6852

0.1292

0.1249

0.2076

0.2774

0.2905

0.3141

0.3571

0.4085

0.4162

0.4471

0.4682

0.4709

0.4829

0.4936

0.5014

0.0773

0.1701

0.2331

0.3254

0.3803

0.4062

0.4851

0.5014

0.5273

0.5523

0.5973

0.6073

0.6243

0.6429

0.6824

>65 years

Gender

Race

Education
level
Less than high
school
High school

College

0.0903

0.2049

0.4612

0.5847

0.6324

0.7642

0.8486

0.8813

0.8936

1.0174

1.0985

1.1085

1.0972

Table 15. Projected e-cig prevalence for each year in the simulation period within different demographic categories of late former cigarette smokers.

1.1023

1.1102

Prevalence estimates for each year
Years
Overall Percent
Prevalence
Standard
errors

1
0.1239
0.152

2

3

0.5103

0.6944

0.167

0.183

4
1.0115
0.175

5

6

7

8

9

1.1284

1.3058

1.3778

1.4019

1.4835

0.184

0.174

0.168

0.196

0.173

10
1.5086
0.182

11

12

13

14

15

1.5619

1.6731

1.7116

1.7513

1.8092

0.154

0.181

0.182

0.168

0.185

Age
6-20 years

0.0749

0.3329

0.4286

0.6572

0.7224

0.7975

0.8089

0.8241

0.8537

0.8729

0.8763

0.914

0.9557

0.9605

0.9856

21-35 years

0.049

0.1774

0.2658

0.3543

0.4654

0.5142

0.5772

0.5878

0.6347

0.6392

0.6842

0.7598

0.7545

0.7981

0.8152

Male

0.0453

0.2216

0.3227

0.4398

0.5021

0.6297

0.6765

0.6816

0.7181

0.7278

0.7515

0.7841

0.8071

0.8234

0.8372

Female

0.0717

0.2974

0.3717

0.5728

0.6263

0.6736

0.7008

0.7203

0.7695

0.7813

0.8173

0.8864

0.9054

0.9276

0.9634

White

0.0616

0.2274

0.2894

0.3991

0.4372

0.5106

0.5617

0.5832

0.5993

0.6076

0.6143

0.6928

0.7014

0.7153

0.7386

Black

0.0175

0.1104

0.1912

0.2857

0.3111

0.3735

0.3733

0.3717

0.4169

0.4247

0.4562

0.4734

0.4871

0.4985

0.5221

Other

0.0379

0.1635

0.2238

0.3467

0.3756

0.4212

0.4428

0.4561

0.4873

0.4862

0.4913

0.5138

0.5243

0.5382

0.5472

Education
level
Less than high
school

0.0667

0.2259

0.3171

0.4511

0.5161

0.6135

0.6449

0.6571

0.6738

0.6917

0.7114

0.7643

0.7841

0.7937

0.7925

High school

0.0416

0.1845

0.2267

0.3252

0.3583

0.3835

0.4051

0.4224

0.4307

0.4415

0.4521

0.4721

0.4876

0.4908

0.4921

College

0.0087

0.1175

0.1606

0.2452

0.2638

0.3148

0.3236

0.3251

0.3801

0.3748

0.4072

0.4362

0.4472

0.4421

0.4529

Gender

Race

Table 16. Projected e-cig prevalence for each year in the simulation period within different demographic categories of never cigarette smokers.

Using Arena
The Arena modeling environment can be started from the Start menu and navigated to
Programs > Rockwell Software > Arena. The Arena modeling environment will open with a
new model window

To model the process in Arena, we work in three main regions of the application window.
The Project Bar hosts panels with the primary types of objects that we work with: The
basic Process panel contains the modeling shapes, called modules that are used to define
the process. Reports panel contained the reports that are available for displaying results of
simulation runs. Navigate panel allows to display different views of the model, including
navigating through hierarchical sub-models and displaying a model thumbnail.

Building the model in Arena

1) Creating the smokers
First part consisted of generating 100,000 smokers and assigning an exponential
distribution to their time of arrival.

2) Sending the smokers into one of the four smoking groups
Next, based on the NHIS distribution of CS, RFS, LFS and NS, the generated smokers
were sent into one of the 4 branches.

3) Assigning the baseline characteristics
Next step was to assign the baseline characteristics to the smokers based on the NHIS
estimates, and assigning corresponding probability distributions. Following figure
shows the assignment of baseline characteristics and smoking related characterstics to
CS. Similar assignments were done to RFS, LFS and NS.

4) Assigning history
Next step in CS was to assign history of quit attempts to the generated population of
current smokers. The quit attempts history were assigned in a way that any new
attempt made inside the simulation model will be added on to the previous quite
attempts incorporated in the history.

5) Risk assignment
The following figure shows how to assign the risk/mutually unexclusive probabilities
based on the baseline and smoking related attributes.

The following figure shows the assignment of risks related to different levels of age
groups, by indexing the risks in 5 different rows corresponding to 5 different age
groups.

6) Decide the initiation of e-cig
This was decided by applying the probability equations discussed in the methods
section. The equation was inserted to percent true module as shown in the figure below.

7) Quit attempt and relapse within one year
This was done by allowing 48% of smokers to pass through the true branch and rest
52% to pass through the false branch. Within those 48%, 9% were allowed to pass
through without making a relapse. Rest of them made a relapse and went into the loop
again.

8) Increase in risk of initiation with every relapse
The risk of initiating an e-cig in the next year increased with every quit attempt made in
the simulation. This was assigned as shown below.

9) Recording prevalence

People who made a relapse and who were continuing to use e-cig were recorded as ecig users, and were recorded as regular e-cig user.

10)

Waiting for another year

After the end of 1 year, smokers were allowed to wait for one year and assigned a new
age.

11) Modeling the effect of policy
The policy effect was modelled by assigning an overall risk which reduced by 1% each
year, a person decided to wait to initiate the e-cig.

12) Setting up the simulation

Finally, the run is set up by filling up the details in the run setup window. The model
was made to run 100 replications for each group for each cycle. The vales can be
changed by the users as per the objectives. The model clock and initial date could be
assigned as shown below.

